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Abstract
A speciﬁc concept of strain was developed in order to classify the BTV serotypes ever reported in
Europe based on their properties of animal health impact: the genotype, morbidity, mortality, speed of
spread, period and geographical area of occurrence were considered as classiﬁcation parameters.
According to this methodology the strain groups identiﬁed were (i) the BTV strains belonging to
serotypes BTV-1–24, (ii) some strains of serotypes BTV-16 and (iii) small ruminant-adapted strains
belonging to serotypes BTV-25, -27, -30. Those strain groups were assessed according to the criteria
of the Animal Health Law (AHL), in particular criteria of Article 7, Article 5 on the eligibility of
bluetongue to be listed, Article 9 for the categorisation according to disease prevention and control
rules as in Annex IV and Article 8 on the list of animal species related to bluetongue. The assessment
has been performed following a methodology composed of information collection, expert judgement at
individual and collective level. The output is composed of the categorical answer, and for the questions
where no consensus was reached, the different supporting views are reported. The strain group BTV
(1–24) can be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the
AHL, while the strain group BTV-25–30 and BTV-16 cannot. The strain group BTV-1–24 meets the
criteria as in Sections 2 and 5 of Annex IV of the AHL, for the application of the disease prevention
and control rules referred to in points (b) and (e) of Article 9(1) of the AHL. The animal species that
can be considered to be listed for BTV-1–24 according to Article 8(3) are several species of Bovidae,
Cervidae and Camelidae as susceptible species; domestic cattle, sheep and red deer as reservoir hosts,
midges insect of genus Culicoides spp. as vector species.
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Summary
The European Commission has requested the European Food Safety Authority (EFSA) to provide an
updated scientiﬁc advice on bluetongue (BT), due to the recent disease evolution in the European
Union (EU), the experience gained from the BT control policies and possible alternative methods to
ensure safe trade of live animals from BT restricted zones. The scientiﬁc advice asked from EFSA
should serve to review the overall BT policy at the EU level. The terms of reference of this request
covered different topic areas, in particular related to (1) BT control policy through vaccination and
surveillance; safe trade of animals moved from BT virus (BTV) infected to BTV-free country or zone,
both (2) about animal immunity and (3) protection from BTV vectors; (4) classiﬁcation of BT serotypes
and (5) BT listing and categorisation in the framework of the Animal Health law (AHL). The ﬁrst three
categories were covered in a previous opinion, the present one covers the fourth and ﬁfth topic area.
As regards the topic about classiﬁcation of BT serotypes, it was requested to review and provide an
update of existing serotypes in the EU and elsewhere. This was done by describing, based on the
relevant literature, the existing BT serotypes that have been or are present in Europe and in
neighbouring countries in chronological order and in relation to the country or area of occurrence.
Secondly, it was requested to assess, by using appropriate criteria, the feasibility of grouping the
currently known BTV serotypes in appropriately deﬁned groups of serotypes sharing similar properties
concerning the impact on animal health. If the serotype classiﬁcation is useful for the production of
serotype-speciﬁc vaccines, the classiﬁcation based on serotypes to assess the different level of impact
is not sufﬁcient to fully represent the genomic diversity and pathogenic heterogeneity of BTV. In the
past, in fact, different virus strains belonging to the same serotypes have caused very different
pictures in terms of animal health impact in Europe and elsewhere. Rather, for this purpose, a speciﬁc
concept of ‘strain’ has been developed: this includes the classiﬁcation according to serotype, genetic
diversity (genotype) together with other aspects of epidemiological relevance, morbidity, mortality,
case-fatality rates, host spectrum, the speed of spread, the period and the geographical area of
occurrence, and their ability to actively circulate within different episystems, as calculated from Animal
Disease Notiﬁcation System (ADNS) data. These epidemiological parameters were expressed
quantitatively for both cattle and small ruminants, and they were ranked and combined to calculate a
pathogenicity score in order to estimate a measure of the impact on cattle and small ruminants.
According to this methodology, the proposed grouping based on BTV strains as deﬁned in the present
opinion is:
• BTV strains belonging to serotypes BTV-1, -2, -4, -8, -9 that have circulated or are still
circulating in some parts of Europe.
• Some strains of serotypes BTV-16 still circulating in some parts of Europe.
• Small ruminant-adapted strains (BTV strains belonging to serotypes BTV-25, -27, -30 and
related isolates).
According to the outcome of the assessment mentioned above, it was requested to assess whether
any of the above serotypes/groups of serotype could be candidates for a partial or total exclusion from
the overall BT policy currently in place in the EU, linked to their low level of virulence or pathogenicity.
According to the assessment here presented, the only BTV serotypes that could be partially excluded
from the overall BT policy currently in place in the EU, due to their low level of virulence or
pathogenicity, are the small ruminant-adapted strains (serotypes BTV-25, -27, -30). Nevertheless,
surveillance is needed both within the EU and in neighbouring areas that can be a source of future
incursions both to provide a better understanding/prediction of the likelihood of an incursion into
Europe, as well as to detect new BT outbreaks within Europe, to identify both their signiﬁcance
(severity, rate of spread, serotype, genotype and host species involvement) and to develop appropriate
control strategies. For this purpose, appropriate surveillance strategies/methods, including sentinels
and the importance of passive surveillance, should be reﬁned and publicised, as well as a
well-established and identiﬁed surveillance network to detect outbreaks at an early stage, in order to
characterise the virus in cause and to assess their relative economic importance and their impact on
animal health. If new outbreaks can be identiﬁed early on, an appropriate ‘ring vaccination’ strategy
could be developed to reduce/prevent viral spread and the potential for further outbreaks. If a broader
cross-reactive (cross-serotype) BTV vaccine, ideally with DIVA capability and long shelf-life, could be
developed, this would potentially reduce the number of different vaccine preparations required and
therefore potentially reduce the costs of a vaccine bank.
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The strain groups identiﬁed above, are further considered for the assessment of Term of Reference
(ToR) 5, i.e. the assessment on listing and categorisation of BT in the framework of the AHL, in
particular about the criteria of Article 7 on disease proﬁle and impacts, Article 5 on the eligibility of BT
strain groups to be listed, Article 9 for the categorisation of BT strain groups according to disease
prevention and control rules as in Annex IV and Article 8 on the list of animal species related to BT.
The assessment has been performed following a methodology composed of information collection
and compilation, expert judgement on each criterion at individual and, if no consensus was reached
before, also at collective level. The output is composed of the categorical answer, and for the
questions where no consensus was reached, the different supporting views are reported. Details on
the methodology used for this assessment are explained in a separate opinion.
According to the assessment here performed, the strain group BTV (1–24) can be considered
eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL, while the strain
group BTV-25–30 and BTV-16 do not comply with criterion A(iii) of Article 5 and therefore cannot be
considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL.
According to the assessment here performed, the strain group BTV (1–24) meets the criteria as in
Sections 2 and 5 of Annex IV of the AHL, for the application of the disease prevention and control
rules referred to in points (b) and (e) of Article 9(1) of the AHL. Since BTV-25–30 and BTV-16 cannot
be considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL, the
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL is not applicable.
According to the assessment performed here, the animal species that can be considered for listing
for BTV-1–24 according to Article 8(3) of the AHL are several (potentially all) species of Arctiodactyla
belonging to the families of Bovidae, Cervidae and Camelidae as susceptible species; domestic cattle,
sheep and red deer as reservoir hosts; midges insect of genus Culicoides spp. as vector species for
BTV-1–24.
Since BTV-25–30 and BTV-16 cannot be considered eligible for listing for Union intervention as laid
down in Article 5(3) of the AHL, the assessment of the animal species that are considered to be listed
in accordance with Article 8 of the AHL is not applicable.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
Over the past 20 years, bluetongue (BT) incursions of a variety of serotypes occurred and on
several occasions became widespread across many parts of Europe. Affected countries sometimes
adopted diverse control policies, particularly as regards vaccination against the disease in order to
cope with both the short as well as the long-term consequences in animal health, animal production
and trade of live animals or their products. Incidences of BT during this period have included
unexpected epidemics in areas, where it had not appeared for more than 10 years (e.g. blue tongue
virus 4 (BTV-4) in the mainland of the Balkan Peninsula in 2014), but also low-impact circulation of
certain serotypes (some of them of unclear origin), incursions of new serotypes, vaccine incidents and
disease resurgence (BTV-8 in France in 2015), raising concerns and evidencing new challenges.
The European Commission has repeatedly sought scientiﬁc advice on BT from the European Foods
Safety Authority (EFSA) in the last decade and in response, EFSA has produced a number of scientiﬁc
opinions dealing with various aspects of BT epidemiology, surveillance and control, which provided
valuable conclusions and recommendations that have helped to shape the current disease strategy at
the European Union (EU) level. Nevertheless, an update appears necessary in the light of the recent
disease evolution, the current epidemiological situation, the experience gained so far from the
implementation of the various BT control policies and possible alternative methods to ensure safe trade
of live animals from BT-restricted zones and the latest scientiﬁc information available. The need to
review the overall BT policy at EU level is an issue that has been repeatedly emphasised by national
authorities of many Member States (MSs), and the IV International Conference on Bluetongue and
related orbiviruses (Rome, 5–7 November 2014) represents a major milestone for taking stock of the
latest state of the art science on BT.
In order to streamline the way forward, the Commission with the MSs have identiﬁed a series of issues
for which concrete elements of science may provide a good basis for reformulating policies and/or
adapting current rules. These are as follows:
1) Safe trade provisions
As regards provisions for safe trade, in particular from BT-restricted areas, the European
Commission, on top of those already in place in Commission Regulation (EC) 1266/2007, is keen to
explore other options used by the competent authorities of some EU Member Countries in the
framework of bilateral trade agreements drafted in accordance with Article 8 of the same Regulation.
Article 8 of Commission Regulation (EC) No 1266/2007 foresees that exemptions from the exit ban are
to be based on risk mitigating measures presented in Annex III to the Regulation or on any other
appropriate animal health guarantees based on a positive outcome of a risk assessment agreed
between the competent authority of the place of origin and the competent authority of the place of
destination. Currently, there are such agreements on the movement of live animals concluded between
France and Italy of 2015, France and Spain of 2013 and 2015, Italy and Spain of 2012, Spain and
Portugal of 2014, France and Luxembourg of 2015 and Italy and Austria of 2016.
2) Classiﬁcation of different BTV serotypes
There are indications that more than 27 different serotypes of the BTV have been identiﬁed to date.
Each of these serotypes, apart from its speciﬁc genetic and antigenic features, may also be connected
with speciﬁc epidemiological and pathogenicity properties. It is necessary to understand whether it is
possible to use these properties as a set of standard criteria to divide known BT serotypes in groups, each
deserving a distinct treatment as regards surveillance, protection and control measures.
3) BT listing and categorisation in the framework of the AHL
In addition to the classiﬁcation of the different serotypes, BT merits an assessment as part of the
listing and categorisation exercise of animal diseases in the framework of the Animal Health Law (AHL)
in the same manner as it was requested previously for another seven diseases (Ref. SANTE G2/BL/lp
(2015) 4940871).
In the light of the above-mentioned ongoing procedure, the Commission is in need of scientiﬁc
advice on the assessment of the signiﬁcance of BT (as an integral disease, or separately for each
serotype or group of serotypes, depending on the outcome of the grouping exercise) also within the
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framework of the listing and categorisation according to the AHL. The criteria, provided for ease of
reference in Annex II and Attachments I to IV thereof, shall be used as a basis for this analytical
assessment. The risk manager needs an updated scientiﬁc advice in order to:
1) assess if the various serotypes or groups of serotypes of BTV cause diseases for which
control measures at the EU level are justiﬁed;
2) proceed with the proﬁling of the diseases caused by the serotypes or groups of serotypes of
BTV as above in view to their categorisation; and
3) assign listed species to the various serotypes or groups of serotypes of BTV identiﬁed as
eligible for EU intervention.
1.1.1. Terms of Reference
In view of the above, and in accordance with Article 29 of Regulation (EC) No 178/2002, the
Commission asks EFSA for a scientiﬁc opinion under the following headings:
1. As regards vaccination, eradication and surveillance
1.1 Assess the most suitable duration of a BT vaccination campaign intended to achieve disease
freedom in a country or region considering any relevant factors that may affect and inﬂuence disease
spread, and persistence.
1.2 Assess the probability of BT recurrence in BT-affected areas that have regained BT freedom, in
particular due to BT virus becoming endemic with low level circulation in these areas and reoccurring
‘spontaneously’ (low-noise circulation in livestock or wildlife, maintenance in vectors or other possible
mechanism to be considered).
1.3 Revise and assess the suitability of the provisions on surveillance laid down in Regulation (EC)
No 1266/2007 to ensure reliable and robust demonstration of absence of virus transmission in a MS or
epidemiologically relevant area, considering point 1.2 above.
2. As regards speciﬁc options for safe trade that could be used for exemptions from
the exit ban applicable to movements of live animals from a restricted zone
2.1 Assess whether maternal immunity against BT in calves, lambs and kids born to, and colostrum
fed from, vaccinated mothers, constitutes a sufﬁcient guarantee for animals of the above species to be
moved safely from a BTV-infected to a BTV-free country or zone, without a risk for disease spread,
with or without the need for any additional premovement testing regime and indicate the main
parameters that could be used (minimum/maximum age of calves, testing of dams, etc.).
2.2 Assess the minimum age of calves, lambs and kids after which residual colostral antibodies
against BTV do not interfere any longer with vaccine immunisation of these animals (in an example of
BT bilateral agreement this age limit is set at 90 days).
2.3 Assess the minimum time after completion of the primary vaccination (1–2 doses as indicated
by the vaccine manufacturer) for the vaccinated animals to be considered immune to be safely moved
from a BT-infected to a BT-free country or zone (currently set at 60 days in paragraph 5 of Annex III
to Regulation (EC) No 1266/2007).
2.4 Assess whether vector protection for 14 days of ruminants below the age of 70 days, combined
with a negative polymerase chain reaction (PCR) test at the end of the 14 days or more, qualify them
for a safe movement from a BT-restricted to a BT-free area.
3. As regards protection from BTV vectors and vector-based provisions for exemption
from the exit ban applicable to movements of live animals from a restricted zone
3.1 Review and update previous opinions as regards vectors ecology (models for distribution/density),
in order to have more accurate and applicable criteria for the determination of the seasonally vector-free
period.
3.2 Review and update previous opinions as regards over-wintering mechanisms and the duration
of the BT viraemia.
3.3 Review and update previous opinions and provide a scientiﬁc assessment of the
appropriateness of the use of insecticides and repellents against Culicoides as BT competent vectors,
including an assessment of their efﬁcacy and recommendations of adequate protocols for their uses, in
particular as regards their suitability to protect animals against attacks by vectors performing at least
equal to the protection provided by vector-proof establishments – without the need to keep animals in
a vector protected facility.
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4. As regards classiﬁcation and grouping of different BTV serotypes according to their
potential impact on animal health
4.1 Review and update previous opinions providing a short description of existing serotypes in the
EU and elsewhere.
4.2 Assess, by using appropriate criteria, the feasibility of grouping the currently known BTV
serotypes in appropriately deﬁned groups of serotypes sharing similar properties thus creating a
number of ‘BTV serotype groups’ separated by signiﬁcant different levels of impact on animal health
(e.g. most serious clinical symptoms in many individuals in large areas, mild symptoms to few
individuals within small areas or no symptoms at all in one or more BT susceptible species etc.).
4.3 Review and classify the existing serotypes according to the outcome of the assessment in point
4.2 above and assess whether any of the above serotypes/groups of serotype could be candidates for
a partial or total exclusion from the overall BT policy currently in place in the EU, in particular due to
their low level of virulence or pathogenicity.
5. Listing and categorisation of BT in the framework of the Animal Health Law.
5.1 Considering the outcome of the assessments and reviews referred to in paragraph 4 above, for
each of the aforementioned groups of serotypes, or BT in general as appropriate, assess, following the
criteria laid down in Article 7 of the AHL, its eligibility of being listed for Union intervention as laid
down in Article 5(3) of the AHL;
5.2 Considering the outcome of the assessments and reviews referred to in paragraph 4 above, for
each of the aforementioned groups of serotypes, or for BT in general, if found eligible to be listed for
Union intervention, provide:
a) an assessment of its compliance with each of the criteria in Annex IV to the AHL for the
purpose of categorisation of diseases in accordance with Article 9 of the AHL;
b) a list of animal species that should be considered candidates for listing in accordance with
Article 8 of the AHL.
1.2. Interpretation of the Terms of Reference
The ﬁrst three Terms of Reference (ToRs) have been addressed in a previous opinion (EFSA AHAW
Panel, 2017a), while the present opinion answers the ToR 4 and 5. The BTV serotypes that will
be considered in this opinion are the ones that have been reported in the EU (BTV-1, BTV-2, BTV-4,
BTV-8, BTV-9, BTV-16, BTV-25, BTV-26 and novel strains). Vaccine strains are not considered in this
document since they are not disease-causing agents and hence are not under the scope of the
mandate. Nevertheless it should be considered that:
• Live vaccine strains like BTV-11, -14, -6 (which have disappeared from the EU) and -16 (which
is still circulating in the EU), may still spread in the ﬁeld, and entail possible risks.
• The viruses circulating in the ﬁeld can also reassort (exchange genetic material) with live
vaccine virus(es), generating novel strains with unknown characteristics.
• Since live BTV vaccines are no longer used in the EU, in case of re-occurrence, these would be
considered as ﬁeld strains.
The assessment on ToR 4.1 reviewing existing serotypes that have been or are present in Europe
and in neighbouring countries is presented in Section 3.1. The occurrence of BT epidemics for each
serotype is described in chronological order and in relation to the country or area of occurrence.
The ToR 4.2 on the assessment of grouping the currently known BTV serotypes according to
signiﬁcant different levels of impact on animal health is discussed in Section 2.2 where the principle
and the criteria for grouping BT serotypes and strains are discussed. The outcome of this is presented
in Section 3.2, which addressed the ToR 4.3 about the classiﬁcation of the existing serotypes and
strains and assesses whether any of these could be candidates for a partial or total exclusion from the
overall BT policy currently in place in the EU, due to their low level of virulence or pathogenicity.
The assessment on ToR 5 about listing and categorisation of BT in the framework of the AHL is
addressed in Sections 3.3 (assessment on Article 7 criteria of AHL), 3.4, 3.5 and 3.6. The approach
followed is that used for other opinions dealing with assessment of listing and categorisation according
to the AHL (EFSA AHAW Panel, 2017b).
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2. Data and methodologies
2.1. Data
The data used in this opinion are taken from the scientiﬁc literature on BT, from the Animal Disease
Notiﬁcation System (concerning epidemiological data on BT reported from MSs), and from previous
EFSA opinions on bluetongue (EFSA AHAW Panel, 2017a). Data reported in the presentations given
during the meetings of the Standing Committee on Plants, Animals, Food and Feed1 are also
considered.
2.2. Methodologies
BTV is classically subdivided in different serotypes according to the immunological and
neutralisation characteristics of viral protein (VP) 2, which is the major protein involved in stimulating
the production of serotype-speciﬁc neutralising antibodies in vertebrate hosts. Given the lack of
effective cross-protection mechanisms between serotypes, the serotype classiﬁcation is extremely
useful for the identiﬁcation and production of serotype-speciﬁc vaccines that are able to protect
against the homologous BTV. However, the classiﬁcation based on serotypes is not sufﬁcient to fully
represent the genomic diversity and pathogenic heterogeneity of BTV. Therefore, considering that, an
assessment of the impact of different ‘types’ of BTV is requested, a speciﬁc concept of ‘strain’ has
been developed, merging the classiﬁcation according to serotype, genetic diversity (genotype)
together with other aspects of epidemiological relevance, including the period and the geographical
area of occurrence. In the past, in fact, different virus strains belonging to the same serotypes have
caused very different pictures in terms of animal health impact in Europe and elsewhere.
For example the BTV-1 circulating in Greece in 2001 that showed genetic similarities to eastern
(Indian) viruses, caused minor consequences on animal health and was associated to mild clinical signs
in sheep only. In 2007, another BTV-1 of different provenance (related to African strains), however,
spread from Morocco through the Iberian peninsula to France, and persisted in these territories for a
number of years, causing signiﬁcant animal health problems due to its capacity to produce severe
disease in sheep ﬂocks. These two BTV strains are genetically diverse, despite belonging to the same
serotype.
Although the analytical work done can characterise each BTV strain, it is noteworthy to clarify that
BTV infection is a dynamic process. The interaction between virus and host is a process that is under
constant adaptation and evolution. Different virus lineages can interact genetically, and are continuing
to evolve. The immune status and the susceptibility of the local ruminant host population may also
change signiﬁcantly. It may therefore be difﬁcult to extrapolate evidence from the past for a speciﬁc
BTV strain, to a future occurrence, unless with clear linkages in time and space. On the other hand,
the behaviour of a certain BTV serotype or strain, including its ability to spread in a new, previously
unaffected, area cannot be reliably estimated on the basis of what happened in other territories.
Animal health impact is a complex combination of several factors working together in that speciﬁc
circumstance and epidemiological system.
Still, the connection between genomic information with ﬁeld-biological information is important:
some laboratory tools can support the differentiation of biological characteristics, although at the
moment it is not possible to identify clear genetic markers or biological tests for predicting virulence,
severity and rate of spread of an outbreak in the ﬁeld. Therefore, observations during the early stage
of an outbreak are potentially the most important indicators of the threat to animal health.
The parameters considered for assessing the animal health impact were morbidity, mortality and
case-fatality rates, calculated on the basis of the Animal Disease Notiﬁcation System (ADNS) data in
each outbreak and for each BTV strain. Moreover, in order to assess the spread capacity of the BTV
strains, the mean number of outbreaks per week, as reported to ADNS, was considered, together with
the ability to actively circulate within different epidemiological systems (episystems). The concept of
episystem was initially proposed by Tabachnick et al. (2004) and recognises that speciﬁc BTV strains
may be better adapted to, and therefore to some extent restricted to, certain geographic regions.
These adaptations reﬂect the speciﬁcity of their interactions with the local vector and host populations,
which may be inﬂuenced by climate and other factors, as demonstrated by previous BTV history and
1 https://ec.europa.eu/food/animals/health/regulatory_committee/presentations_en
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the identity of circulating strains in the region. For the purposes of the present opinion and focussing
on the European continent and the Mediterranean Basin, three major episystems can be observed:
• South-western European episystem, including the western Mediterranean area and
characterised by the relatively high abundance of the major BT vector, Culicoides imicola, large
sheep populations and high probability of exposure to the introduction of BTV strains from
northern African countries, frequently through infected midges disseminated by winds.
• South-eastern European episystem, covering the Balkan and the eastern Mediterranean zones,
characterised by an heterogenicity of vector species involved in the BTV transmission, with the
presence of C. imicola in limited areas of Greece and Turkey and the presence of other species
belonging to the Obsoletus and Pulicaris complexes in the other zones of the area, a lower
density of sheep population and the exposure of the incursions of BTV strains from Asia and
Middle East.
• Northern and central European episystem, characterised by the transmission of BTV by
Culicoides species belonging to the Obsoletus and Pulicaris complexes and other cattle-related
species, such as C. chiopterus and C. dewulﬁ, and climatic conditions in general less favourable
to Culicoides borne diseases.
It must be underlined that the three above reported episystems cannot be considered an
exhaustive description of BTV epidemiological niches present in Europe. They have been chosen given
the purposes of this study. Considering a smaller scale and geographical resolution, in fact, multiple
BTV episystems could be identiﬁed, for example, in countries with highly geographic and climatic
variations, like Italy (south-east and south-west).
Regarding grouping BTV strains based on levels of impact on animal health, the main criteria
concerning pathogenicity, epidemiological properties and geographical spread have been considered
for assessing the animal health impact of BTV strains as described in the Section 2.2.
The pathogenicity of each strain has been assessed considering the severity of clinical symptoms in
the main susceptible species (domestic cattle and small ruminants), as measured by the within-herd
morbidity, mortality and case fatality rates, calculated from the ADNS data. These rates are expressed
quantitatively for both cattle and small ruminants as median, 5th and 95th percentiles. Based on the
95th percentile of each epidemiological parameter, a pathogenicity score is calculated in order to
estimate a measure of the impact on cattle and small ruminants, as explained in the table legend
(Table 2).
Data on production and reproduction losses different from direct mortality of animals (e.g. weight
and/or milk loss or losses linked to fertility reduction) is limited and available only for BTV-8, and
therefore these aspects have not been taken into account in this analysis (Rushton and Lyons, 2015).
Moreover, as a measure of speed of spread, the mean number of outbreaks per week reported to
ADNS (in the period where no vaccination was implemented) has been calculated and categorised in
three classes (low, medium and high) according to < 50 outbreaks/week, between 50 and 150
outbreaks/week, and > 150 outbreaks/week.
Some further aspects related to epidemiological properties have been considered: the transmission
routes (vector-borne or direct), the capability of spread in different episystems and the host spectrum.
For the purposes of what requested by ToR 4, the above reported criteria have been used to
categorise the main BTV strains on the basis of the animal health impact.
Considering the impossibility of categorising a priori BTV strains from their pathogenicity capacity
point of view, an empirical approach was followed in the present opinion, by analysing the observed
and notiﬁed data on BTV outbreaks in the EU. This approach can be affected by some biases, not only
due to the underreporting phenomenon, but also because what observed in the different
circumstances was strictly related to the speciﬁc and local epidemiological conditions, such as
abundance and distribution of competent vectors, density of susceptible animal hosts, period of the
year of BTV introduction into the susceptible population. This approach, therefore, cannot be able to
predict the impact the infection due to the same serotype in different epidemiological conditions and
the conclusions that can be driven from the current assessment are limited to what already observed
in the past in the EU.
Regarding ToR 5, the methodology applied in this opinion is described in detail in a dedicated
document about the ad hoc method developed for assessing any animal disease for the listing and
categorisation of diseases within the AHL framework (EFSA AHAW Panel, 2017b).
It is noteworthy to highlight that although the impact on different animal species has been not
considered separately in the assessment according to article 5 and 9 criteria, BTV infection results in a
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clearly distinct clinical picture between sheep and cattle. In the latter, in fact, with the sole exception
of BTV-8 epidemic in France, Belgium, Germany and the Netherlands in 2006–2008, clinical cases are
usually rare and the mortality absent.
3. Assessment
3.1. Review of existing BTV serotypes
This section described the main serotypes that have occurred in Europe and in the Mediterranean
basin and neighbouring countries. Historically (prior 1998), Europe had experienced only sporadic
incursions of BT, involving a single virus serotype on each occasion (Mellor and Boorman, 1995).
A major outbreak caused by BTV-10 ravaged the sheep populations of Spain and Portugal between
1956 and 1960, causing the deaths of almost 180,000 animals (Manso-Ribeiro et al., 1957) and a
smaller outbreak of BTV-4 occurred on several Greek islands near the Anatolian Turkish coast in 1979
(Vassalos, 1980). However, since 1998, BTV has spread northwards into the Mediterranean Basin, with
new strains of ﬁve BTV serotypes (1, 2, 4, 9 and 16) have been identiﬁed in each successive years
(Purse et al., 2005). BTV-9 ﬁrst entered eastern Europe (Greece) in 1998. Between 1999 and 2002,
this strain spread from Greece to Bulgaria invading all of the Balkan Peninsula and southern mainland
Italy (November 2000–2001).
In Greece, BTV-16, BTV-4 and BTV-1 strains were also isolated in 1999, 2000 and 2001,
respectively (Panagiotatos, 2004). In 2000, BTV-2 was conﬁrmed for the ﬁrst time ever in Italy. The
island of Sardinia was affected ﬁrst but by October, BTV-2 had also spread to Sicily and southern
mainland Italy. BTV-2 was also recorded for the ﬁrst time on the French island of Corsica, and on the
Spanish islands of Menorca and Mallorca. Just as in Italy, the outbreaks in the Balearics continued into
November and December 2002 (Mellor, 2004).
In 2002, BTV-16 was also reported from southern Italy (Puglia). BTV-16 seroconverted sentinel
animals were found in October 2003 (OIE, 2004a) in Cyprus. In February 2004, a new outbreak of BT
occurred in Larnaca district, also in the eastern part of the country. In January 2004, circulation of BTV-16
in Sardinia was detected by virus neutralisation test in seven sentinel animals (Calistri et al., 2004a). In
the summer of the same year, BTV-16 (vaccine strain) was detected also in Corsica (OIE, 2004b).
In September 2003, circulation of BTV-4 was detected in Sardinia (OIE, 2003a), in October BTV-4
was identiﬁed at the laboratory of the French Agency for Food Safety (AFSSA) (OIE, 2003b). In the
same year, BTV-4 was also identiﬁed from the Spanish Balearic islands.
A vast epidemic of BTV-4 in 2004 involved also the northern part of Morocco (OIE, 2004c),
spreading from there into the southern part of the Iberian Peninsula (OIE, 2004d,e).
The phylogenetic analyses of BTV detected in the Spanish island of Menorca showed that this was
also a western strain of BTV-4, although it was clearly distinct from strains that had previously caused
outbreaks in the eastern Mediterranean region.2 These conclusions were conﬁrmed by Zientara et al.
(2006) working with Corsican isolates. This virus was believed to have entered Europe from North
Africa. The same strain of BTV-4 subsequently caused outbreaks and was isolated in Morocco and then
spread to the Iberian Peninsula in 2004, where it persisted through into 2005.
In 2006 (October), BTV-1 was recorded in Sardinia (OIE, 2006). This serotype subsequently spread
from Maghreb to southern Spain, where it was detected in the summer of 2007 (OIE, 2007c). BTV-1
continued to spread during 2007 and was detected in Portugal by September (OIE, 2007a) and
south-west France in November (OIE, 2007b). By November 2008, BTV-1 had spread as far as Brittany
in northern France (ISID, 2008).
In the summer of 2006, for the ﬁrst time, BTV crossed latitude 50°N and outbreaks caused
by BTV-8 occurred in north-western Europe: the Netherlands, Belgium, Germany, France, and
Luxembourg (Wilson and Mellor, 2008). In 2007–2008, the BT situation changed for the worse, BTV-8
spread to the other regions of Europe and the number of outbreaks increased rapidly. Additionally, two
new BTV serotypes, BTV-11 and BTV-6 (both South African vaccine strains) were detected (Wilson and
Mellor, 2009). However, the implementation of BT vaccination programmes in Europe resulted in a
massive reduction of BTV-8 cases, and even eradication in some countries.
In 2012, BTV-1 and BTV-4 were identiﬁed in Sardinia and BTV-14 (vaccine strain) in Lithuania,
Latvia, Poland and Spain. In 2013, disease caused by BTV-1 spread extensively over the territory of
2 www.iah.bbsrc.ac.uk/dsRNA_virus_proteins/ReoID/btv-4.htm; http://www.iah.bbsrc.ac.uk/dsRNA_virus-proteins/ReoID/BTV-mol-
epidem.htm
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Italy (Sardinia, Sicily and mainland Italy). At the beginning of 2014, the same BTV serotype was
isolated in Corsica (France). Moreover, in 2013, BTV-1 cases were noticed in western Spain, while
outbreaks caused by BTV-4 were observed in southern Spain (Andalusia) and in the region of the
Algarve in Portugal. In 2014, more cases associated to BTV-4 and BTV-1 were recorded in Spain. In
2014, outbreaks of BTV-4 were conﬁrmed in Greece (Peloponnese and Evros regions). In July, the ﬁrst
outbreak of BTV-4 was also reported in the south of Bulgaria and from there it spread to the rest of
Bulgaria, Romania and all of the Balkan countries and southern Italy. In 2015, BTV-4 spread to Austria
and Slovenia and continued circulating in the Balkan Peninsula and Italy, where in 2016 the strain
affected nearly all of the country including the northern regions and part of Sardinia.
In 2015, despite 5 years of supposed absence, BTV-8 re-emerged in France and in 2016 spread
further, affecting almost all the country. In 2015 and 2016, few BTV-1 and BTV-4 outbreaks were
recorded in Spain, whereas BTV-1 circulation was still observed in Portugal.
A new BTV strain infecting goats was discovered in Switzerland in early 2008. It was initially named
Toggenburg orbivirus (Hofmann et al., 2008; Chaignat et al., 2009). This strain has been conﬁrmed as
a novel serotype, BTV-25.
In February 2010, another novel BTV serotype was isolated in Kuwait from sheep and named
BTV-26 (virus isolate KUW2010/02) (Maan et al., 2011a). When experimentally infected with BTV-26,
sheep showed only mild clinical disease (Batten et al., 2012). Phylogenetic analyses showed a high
level of divergence in most of the conserved genome-segments between most BTV strains and BTV-26
(KUW2010/02) and/or BTV-25 (SWI/2008/01), placing them as representatives of two novel and
distinct BTV topotypes (Maan et al., 2011b). The kinetics of BTV-26 infection in sheep and goats are
similar to those of BTV-25. Although this virus replicates well in mammalian cells, it does not infect
cells or adults of a vector (Pullinger et al., 2016). However, the virus can be horizontally transmitted to
uninfected, in-contact goats, which subsequently seroconvert (Batten et al., 2013a, 2014). This
indicated that unlike BTV-25, BTV-26 can be transmitted horizontally by direct contact and replicates in
mammalian cells (BHK-21, BSR and Vero cells) in vitro, but does not replicate in KC cells. There is
serological evidence that the distribution of BTV-26 may be more widespread, in cattle and camels in
Mauritania (Lorusso et al., 2016).
During the compulsory vaccination programme against BTV-1 in Corsica (France) in 2014, a BTV strain
belonging to a previously uncharacterised serotype (BTV-27) was isolated from asymptomatic goats
(Zientara et al., 2014). Three variants of BTV-27 have been described (Schulz et al., 2016). The full
coding genome of the two novel BTV-27 variants (isolated in 2015 in Corsica) show high homology
(90–93% nucleotide/93–95% amino acid) with the originally described BTV-27 isolate from Corsican
goats in 2014. These three variants constitute the novel serotype BTV-27 (‘BTV-27/FRA2014/v01 to v03’).
During Bluetongue surveillance activities, Savini et al. (2017) identiﬁed a putative novel BTV
serotype in healthy goats from Sardinia, Italy. Overall, Seg 2 of BTV-X ITL2015 shows the highest
identity with recently isolated BTV-27s from Corsica and with the last discovered BTV XJ1407 from
China, whereas it is less related with BTV-25 from Switzerland and BTV-26 from Kuwait. Considering
the Seg 2/VP2 identity of BTV-X ITL2015 with BTV-25, 26, 27s and BTV XJ1407 and that serum of
BTV-X ITL2015 infected goats failed to neutralise all tested extant serotypes, the existence of a novel
BTV serotype circulating in goats in Sardinia can be proposed, it should be BTV-30, although not
conﬁrmed yet.
The three serotypes BTV-25, -26 and -27 are genetically grouped. Phylogenetic analyses with the
26 other established BTV serotypes revealed the closest relationship to BTV-25 (SWI2008/01) (80%
nucleotide/86% amino acid) and to BTV-26 (KUW2010/02) (73–74% nucleotide/80–81% amino acid).
However, highest sequence homologies between individual segments of BTV-27/FRA2014/v01–v03 with
BTV-25 and BTV-26 vary. Neutralisation assays of anti-BTV27/FRA2014/v01–v03 sera with a
reassortant virus containing the outer capsid proteins of BTV-25 (BTV1VP2/VP5 BTV25) further
conﬁrmed that BTV-27 represents a distinct BTV serotype.
3.2. Classiﬁcation of existing strains
The output of the analysis as described in Section 3.2 is reported in Tables 1 and 2. Table 1 shows the
data about pathogenicity (morbidity, mortality, case-fatality), epidemiological properties (transmission
routes, host spectrum and no. of outbreak per week) and geographical spread for each BTV strains
reported in Europe and neighbouring countries. Where data are not available is indicated (n.a.). In
Table 2, the data from Table 1 are used to assess the spread capability to different episystem, speed of
transmission, and pathogenicity score for the impact of BTV strains on cattle and small ruminants.
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Table 1: Data about pathogenicity, epidemiological properties and geographical spread for each BTV strains reported in Europe and neighbouring
countries are listed according to chronology of occurrence in the EU since 1999
Serotype
Strains/
isolates
Countries Episystem Period
Host
spectrum
Transmission
route
Mean no.
outbreak/
week
(without
vaccination)
Impact on small ruminants ﬂocks Impact on cattle herds
Median
value
of intra
ﬂock
morbidity
(5th, 95th
percentile)
Median
value of
intra ﬂock
case
fatality
(5th and
95th
percentile)
Median
value of
intra ﬂock
mortality
(5th and
95th
percentile)
Median
value of
intra herd
morbidity
(5th and
95th
percentile)
Median
value of
intra ﬂock
herd
fatality
(5th and
95th
percentile)
Median
value of
intra herd
mortality
(5th and
95th
percentile)
BTV-4 GRE1999/01 EL, TR SE 1998–
2001
Cattle,
SR
Vector-borne 44.46 5.0%
(0.7–
30.8%)
0.0%
(0–100%)
0.0%
(0–10.0%)
n.a. n.a. n.a.
SPA2003/01
SPA2004/01
IT2003/01
ES, IT, FR
(Corsica),
MO, PT
SW 2003–
2005
Cattle,
SR
Vector-borne 72.88 2.8%
(0.3–
20.8%)
0.0%
(0–66.7%)
0.0%
(0–2.6%)
n.a. n.a. n.a.
MOR2009/07 MO, ES,
ALG, TU
SW 2009–
2012
Cattle,
SR
Vector-borne n.a. n.a. n.a. n.a. n.a. n.a. n.a.
IT2012/01 IT
(Sardinia)
SW 2012 Cattle,
SR
Vector-borne n.a. n.a. n.a. n.a. n.a. n.a. n.a.
SPA2013/01 ES, PT SW 2012–
2013
Cattle,
SR
Vector-borne n.a. n.a. n.a. n.a. n.a. n.a. n.a.
CYP2011/01 CY, IL, GR SE 2011–
2013
Cattle,
SR
Vector-borne n.a. n.a. n.a. n.a. n.a. n.a. n.a.
GRE2014/07
IT2014/01
FR2016/01
EL, ALB,
BG, HR,
RU, SE,
SL, AT, IT,
HU, MT,
MK, FR
(Corsica)
SE 2014–
2017
Cattle,
SR
Vector-borne 63.99 5.8%
(0.3–
38.3%)
25.0%
(0–100%)
1.0%
(0–16.2%)
2.7%
(0–50%)
0.0%
(0–100%)
0.0%
(0–100%)
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Serotype
Strains/
isolates
Countries Episystem Period
Host
spectrum
Transmission
route
Mean no.
outbreak/
week
(without
vaccination)
Impact on small ruminants ﬂocks Impact on cattle herds
Median
value
of intra
ﬂock
morbidity
(5th, 95th
percentile)
Median
value of
intra ﬂock
case
fatality
(5th and
95th
percentile)
Median
value of
intra ﬂock
mortality
(5th and
95th
percentile)
Median
value of
intra herd
morbidity
(5th and
95th
percentile)
Median
value of
intra ﬂock
herd
fatality
(5th and
95th
percentile)
Median
value of
intra herd
mortality
(5th and
95th
percentile)
BTV-1 GRE2001/01 EL SE 2001 Cattle,
SR
Vector-borne 12.29 3.9%
(0.8–
18.4%)
0.0%
(0–66.7%)
0.0%
(0–4.6%)
n.a. n.a. n.a.
SPA2007/04;
FR2008/24
IT2006/01
MO, ES,
ALG, TU,
IT
(Sardinia),
PT, FR
N/SW 2006–
2010
Cattle,
SR
Vector-borne 108.42 10.0.%
(0.4–
100.0%)
0.0%
(0–80.0%)
0.0%
(0–5.2%)
6.3%
(0.7–
100%)
0.0%
(0–0%)
0.0%
(0–0%)
IT/2012/01 IT SW/SE 2012–
2014
Cattle,
SR
Vector-borne 179.41 12.3.%
(1.2–
81.2%)
26.9%
(0–100%)
3.8%
(0–23.2%)
4.8%
(0.5–
89.2%)
0.0%
(0–0%)
0.0%
(0–0%)
BTV-2 IT2001/01
IT2001/03
FR2000/01
TU, ALG,
IT, ES
(Balearic
islands),
FR
(Corsica)
SW 1999–
2002
Cattle,
SR
Vector-borne 200.90 1.8%
(0.3–
18.8%)
0.0%
(0–100%)
0.0%
(0–5.9%)
n.a. n.a. n.a.
BTV-9 GRE1999/01
IT2000/01
IT2003/01
TR, EL, IT,
BG, MK,
SE, BiH,
ALB, HR
SE 1999–
2003
Cattle,
SR
Vector-borne n.a. n.a. n.a. n.a. n.a. n.a. n.a.
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Serotype
Strains/
isolates
Countries Episystem Period
Host
spectrum
Transmission
route
Mean no.
outbreak/
week
(without
vaccination)
Impact on small ruminants ﬂocks Impact on cattle herds
Median
value
of intra
ﬂock
morbidity
(5th, 95th
percentile)
Median
value of
intra ﬂock
case
fatality
(5th and
95th
percentile)
Median
value of
intra ﬂock
mortality
(5th and
95th
percentile)
Median
value of
intra herd
morbidity
(5th and
95th
percentile)
Median
value of
intra ﬂock
herd
fatality
(5th and
95th
percentile)
Median
value of
intra herd
mortality
(5th and
95th
percentile)
BTV-16 GRE2000/01 EL, TR SE 1999–
2000
Cattle,
SR
Vector-borne n.a. n.a. n.a. n.a. n.a. n.a. n.a.
IT2002/01 IT, IL SE 2002–
2004
Cattle,
SR
Vector-borne n.a. n.a. n.a. n.a. n.a. n.a. n.a.
FR2004/01
IT2004/01
CRO2004
IT, FR
(Corsica),
HR
SE 2004 Cattle,
SR
Vector-borne 2.27 1.7%
(0.4–
16.3%)
0.0%
(0–70%)
0.0%
(0–2.3%)
n.a. n.a. n.a.
CY2004/01
CY2010/01
CY SE 2003–
2014
Cattle,
SR
Vector-borne n.a. n.a. n.a. n.a. n.a. n.a. n.a.
BTV-8 NL2006/04 NL, BE,
DE, FR,
LU, DK,
CZ, UK,
ES, IT,
NO, SW,
CH, AT
N/SW 2006–
2009
Cattle,
SR
Vector-borne 1,616.05 8.9%
(0.4–
100%)
0.0%
(0–100%)
0.0%
(0–17.0%)
2.1%
(0.4–
100%)
0.0%
(0–0%)
0.0%
(0–0%)
FR2015/01 FR N 2015–
2017
Cattle,
SR
Vector-borne 53.84 3.0%
(0.5–
21.7%)
0.0%
(0–31.3%)
0.0%
(0–2.8%)
0.9%
(0.3–8.4%)
0.0%
(0–0%)
0.0%
(0–0%)
BTV-25 CH2008/01 CH, IT SW 2008–
current
SR Direct n.a. n.a. n.a. n.a. n.a. n.a. n.a.
BTV-27 FR2014/01 F
(Corsica)
SW 2014–
current
SR Direct n.a. n.a. n.a. n.a. n.a. n.a. n.a.
BTV-30 IT2015/01 IT
(Sardinia)
SW 2015–
current
SR Direct n.a. n.a. n.a. n.a. n.a. n.a. n.a.
BTV: bluetongue virus.
Episystems: Northern Europe (N), south-western Europe (SW), south-eastern Europe (SE).
Countries: Algeria (AL), Albania (AB), Austria (AT), Belgium (BE), Bulgaria (BG), Bosnia-Herzegovina (BiH), Switzerland (CH), Cyprus (CY), the Czech Republic (CZ), Germany (DE), Denmark (DK),
Greece (EL), Spain (ES), France (FR), Croatia (HR), Hungary (HU), Israel (IL), Italy (IT), Luxemburg (LU), FYROM (MK), Morocco (MO), Montenegro (MT), the Netherlands (NL), Norway (NO),
Portugal (PT), Romania (RU), Serbia (SE), Slovenia (SL), Sweden (SW), Turkey (TR), Tunisia (TU) and the United Kingdom (UK).
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Table 2: Spread capability to different episystem, speed of transmission, and pathogenicity score for the impact of BTV strains on cattle and small
ruminants
Serotype Strains/isolates
Spread capability
to other episystem(a)
Level of transmissibility(b)
Pathogenicity score
Small ruminants(c)
Pathogenicity score
Cattle(d)
BTV-4 GRE1999/01 Yes Low 5 n.a.
SPA2003/01
SPA2004/01
IT2003/01
Medium 4 n.a.
MOR2009/07 n.a. n.a. n.a.
IT2012/01 n.a. n.a. n.a.
SPA2013/01 n.a. n.a. n.a.
CYP2011/01 n.a. n.a. n.a.
GRE2014/07
IT2014/01
FR2016/01
Medium 6 6
BTV-1 GRE2001/01 Yes Low 5 n.a.
SPA2007/04;
FR2008/24
IT2006/01
Medium 5 2
IT/2012/01 High 6 2
BTV-2 IT2001/01
IT2001/03
FR2000/01
No High 5 n.a.
BTV-9 GRE1999/01IT2000/01
IT2003/01
No n.a. n.a. n.a.
BTV-16 GRE2000/01 No n.a. n.a. n.a.
IT2002/01 n.a. n.a. n.a.
FR2004/01
IT2004/01
CRO2004/01
Low 4 n.a.
CY2004/01
CY2010/01
n.a. n.a. n.a.
BTV-8 NL2006/04 Yes High 6 2
FR2015/01 Medium 3 1
BTV-25 CH2008/01 Unknown n.a. n.a. n.a.
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Serotype Strains/isolates
Spread capability
to other episystem(a)
Level of transmissibility(b)
Pathogenicity score
Small ruminants(c)
Pathogenicity score
Cattle(d)
BTV-27 FR2014/01 Unknown n.a. n.a. n.a.
BTV-30 IT2015/01 Unknown n.a. n.a. n.a.
BTV: bluetongue virus.
(a): The spread capability to other episystem is indicated on the basis of the data presented in Table 1, i.e. in how many episystems BTV strains of the same serotype have been reported (Yes:
reported in more than one episystem; No: reported in only one episystem).
(b): Low = Mean no. outbreak/week < 50; Medium = Mean no. outbreak/week > 50 and < 150; High = Mean no. outbreak/week > 150.
(c): Pathogenicity score calculated as the sum of the following scores:
• intraﬂock morbidity > 15% = score 2; intraﬂock morbidity between 5% and 15% = score 1; intraﬂock morbidity < 5% = score 0.
• intraﬂock case-fatality rate > 50% = score 2; intraﬂock case-fatality rate between 20% and 50% = score 1; intraﬂock case-fatality rate < 20% = score 0.
• intraﬂock mortality > 10% = score 2; intraﬂock mortality between 3% and 10% = score 1; intraﬂock mortality < 3% = score 0.
(d): Pathogenicity score calculated as the sum of the following scores:
• intraherd morbidity > 4% = score 2; intraherd morbidity between 1% and 4% = score 1; intraherd morbidity < 1% = score 0.
• intraherd case-fatality rate > 50% = score 2; intraherd case-fatality rate between 20% and 50% = score 1; intraherd case-fatality rate < 20% = score 0.
• intraherd mortality > 1% = score 2; intraherd mortality between 0.5% and 1% = score 1; intraherd mortality < 0.5% = score 0.
AHL assessment on bluetongue
www.efsa.europa.eu/efsajournal 17 EFSA Journal 2017;15(8):4957
From the analysis, it appears that all BTV strains belonging to the ‘historical’ serotypes (BTV- 1, -2,
-4, -8 and -9) shown in Tables 1 and 2 are characterised by at least one strain with high level of
virulence in at least one of the susceptible species, thus conﬁrming the high variability of BTV in term
of animal health impact according to the different biotic (e.g. host susceptibility, vector species and
abundance) and abiotic conditions (climatic factors). A different case could be some strains belonging
to serotype 16 where data are available for their current circulation in Italy (strain IT2004) and past
circulation in Corsica and Croatia (FR2004 and CRO2004, Listes et al., 2009), which are characterised
by moderate, albeit variable, level of morbidity in small ruminants (median 1.7%; 0.4–16.3, 5th–95th
percentiles), as well as case fatality, and very limited mortality rates, and speed of spread. However,
experimental studies in na€ıve northern European sheep demonstrated that this virus serotype also has
the capacity to be highly virulent, thus in line with what explained in Section 2.2 about the capacity of
BTV serotype/strains to modify the virulence (Veronesi et al., 2010).
Small ruminant-adapted BTV strains belonging to serotypes BTV-25, -27, -30 and related isolates
represent a novel group of the virus that is different from the biological and genetic point of view, they
show very low or null level of virulence or pathogenicity; they have all been isolated in asymptomatic
goats or sheep, and initial evidence indicates that they can be transmitted by contact rather than via
vector insects.
Therefore the proposed grouping based on BTV strains as deﬁned in the present opinion is:
• BTV strains belonging to serotypes BTV-1, -2, -4, -8, -9, that have circulated or are still
circulating in some parts of Europe, as in Tables 1 and 2.
• Some strains of serotypes BTV-16 still circulating in some parts of Europe.
• Small ruminant-adapted strains (BTV strains belonging to serotypes BTV-25, -27, -30 and
related isolates).
These groups are considered for the judgement on AHL criteria as in Sections 3.4, 3.5 and 3.6.
According to the assessment here presented, the only BTV serotypes that could be partially
excluded from the overall BT policy currently in place in the EU, due to their low level of virulence or
pathogenicity, are the small ruminant-adapted strains (serotypes BTV-25, -27, -30).
3.3. Assessment of BT serotype groups according to Article 7 criteria
This section presents the assessment of bluetongue according to the Article 7 criteria of the AHL and
related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017b)), based on
the information contained in the fact sheet as drafted by the selected disease scientist (see Section 2.2 of
the scientiﬁc opinion on the ad hoc methodology) and according to the serotype groups as mentioned in
Section 3.2, the BTV strains belonging to serotypes BTV-1, -2, -4, -8, -9, -16 and the small ruminant-
adapted strains (BTV strains belonging to serotypes BTV-25, -27, -30 and related isolates).
3.3.1. Article 7(a) Disease Proﬁle
3.3.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
The information reported below is applicable to all BTV serotypes.
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
The main vertebrate hosts of bluetongue virus are members of the Artiodactyla (even-toed
ungulates).
Antibodies against BTV have been reported from a wide variety of other artiodactylids, including
members of the Bovidae particularly a number of African antelope species; Cervidae and Camelidae as
well as Girafﬁdae and Antilocapra americana. Less commonly, virus has been isolated from various
species including several species of deer, and llamas, or viral RNA has been detected using reverse
transcription polymerase chain reaction (RT-PCR). Given the broad range of species, potentially all
ruminants and camelids can be infected. Further data concerning the range of species that are
susceptible, including references, is available at Wildlife Information Network.3
Additionally, antibodies to BTV and in some cases viral RNA have also been detected in various
carnivores (cats, dogs, other species), elephants and rhinoceros. BTV was isolated from several species
3 http://wildpro.twycrosszoo.org/S/virus/reoviridae/ReoviridaeBTV/ReoviridaeBTV/03BTVSppDefinitiveHost_Mammals.htm
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of rats, mice, voles, gerbils, etc. (family Muridae), Rhabdomys pumilio and Otomys irroratus in early
work, and from a Crocidura sp. shrew.
The species that were found seropositive:
• White-tailed deer4 , Odocoileus virginianus, Cervidae, Artiodactyla
• Brocket deer, Mazama americana and related species Cervidae, Artiodactyla
• Red deer4, Cervus elaphus, Cervidae, Artiodactyla
• Wapiti elk, Cervus canadensis, Cervidae, Artiodactyla
• Roe deer, Capreolus capreolus, Cervidae, Artiodactyla
• Black-tailed deer, Odocoileus hemionus, Cervidae, Artiodactyla
• Axis deer, Axis axis, Cervidae, Artiodactyla
• Fallow deer, Dama dama, Cervidae, Artiodactyla
• Sika deer2, Cervus nippon, Cervidae, Artiodactyla
• Musk deer, Moschus moschiferus, Cervidae, Artiodactyla
• Moose, Alces alces, Cervidae, Artiodactyla
• Reeve’s muntjac, Muntiacus reevesi, Cervidae, Artiodactyla
• Bighorn sheep4, Ovis canadensis, Bovidae, Artiodactyla
• Mouﬂon4, Ovis orientalis, Bovidae, Artiodactyla
• Blesbuck, Damaliscus albifrons, Bovidae, Artiodactyla
• Blue wildebeest, Connochaetes taurinus, Bovidae, Artiodactyla
• Black wildebeest, Connochaetes gnou, Bovidae, Artiodactyla
• Buffalo, Syncerus caffer, Bovidae, Artiodactyla
• American bison (US: buffalo), Bison bison, Bovidae, Artiodactyla
• European bison/wisent, Bison bonasus, Bovidae, Artiodactyla
• Red hartebeest,4 Alcelaphus buselaphus, Bovidae, Artiodactyla
• Impala4, Aepyceros melampus, Bovidae, Artiodactyla
• Common eland, Taurotragus oryx, Bovidae, Artiodactyla
• Arabian oryx, Oryx leucoryx, Bovidae, Artiodactyla
• Addax, Addax nasomaculatus, Bovidae, Artiodactyla
• Nubian ibex, Capra nubiana, Bovidae, Artiodactyla
• Sable antelope4, Hippotragus niger, Bovidae, Artiodactyla
• Springbok, Antidorcas marsupialis, Bovidae, Artiodactyla
• Pronghorn, Antilocapra americana, Bovidae, Artiodactyla
• Musk ox, Ovibos moschatus, Bovidae, Artiodactyla
• Alpine ibex, Capra ibex, Bovidae, Artiodactyla
• Siberian ibex, Capra sibirica, Bovidae, Artiodactyla
• Spanish ibex, Capra pyrenaica, Bovidae, Artiodactyla
• Blackbuck, Antilope cervicapra, Bovidae, Artiodactyla
• Greater kudu4, Tragelaphus cubensis, Bovidae, Artiodactyla
• Giraffe, Giraffa camelopardalis, Girafﬁdae, Artiodactyla
• Okapi4, Okapia johnstoni, Girafﬁdae, Artiodactyla
• Collared peccary, Pecari tajacu, Tayassuidae, Artiodactyla
• White rhinoceros, Ceratotherium simum, Rhinocerotidae, Perissodactyla
• Black rhinoceros, Diceros bicornis, Rhinocerotidae, Perissodactyla
• African elephant, Loxodonta africana, Elephantidae, Proboscidea
• Asian elephant, Elephas maximus, Elephantidae, Proboscidea
• Cheetah, Acinonyx jubatus, Felidae, Carnivora
• Lion, Panthera leo, Felidae, Carnivora
• Eurasian lynx, Lynx lynx, Felidae, Carnivora
• Florida panther, Puma concolor coryi, Felidae, Carnivora
• African wild dog, Lycaon pictus, Canidae, Carnivora
• Spotted hyena, Crocuta crocuta, Canidae, Carnivora
• Jackal, Canis mesomelas, Canidae, Carnivora
• Large spotted genet (Genetta tigrina), Viverridae, Carnivora
• Black bear, Ursus americanus ﬂoridanus, Ursidae, Carnivora.
4 Clinical disease has been also reported in this species.
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Parameter 2 – Naturally susceptible domestic species (or family/orders)
Among the most common domestic ruminant species bred in the EU, it is generally considered that
Ovis aries (domestic sheep) are the main clinically affected species while Bos taurus (domestic cattle)
can be infected but rarely showing the clinical disease. Capra hircus (domestic goat) also can be
infected. Current data suggests that at least some strains of the novel serotypes (particularly BTV-25)
may show speciﬁcity for goats (Hofmann et al., 2008). Other domestic species found seropositive for
BTV include:
• Water buffalo, Bubalus bubalis, Bovidae, Artiodactyla
• One-humped camel, Camelus dromedarius, Camelidae, Artiodactyla
• Bactrian camel, Camelus bactrianus, Camelidae, Artiodactyla
• Alpaca, Vicugna pacos, Camelidae, Artiodactyla
• Llama, Lama glama, Camelidae, Artiodactyla
• Yak, Bos grunniens, Bovidae, Artiodactyla (also clinical disease detected)
• Domestic dog, Canis familiaris, Canidae, Carnivora
• Domestic cat, Felis catus, Felidae, Carnivora
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
• American bison, Bison bison, Bovidae, Artiodactyla
• Black-tailed deer, Odocoileus hemionus, Cervidae, Artiodactyla
• White-tailed deer, Odocoileus virginianus, Cervidae, Artiodactyla
• Red deer, Cervus elaphus, Cervidae, Artiodactyla
• Wapiti elk, Cervus canadensis, Cervidae, Artiodactyla
• Pronghorn antelope, Antilocapra americana, Bovidae, Artiodactyla
• African buffalo, Syncerus caffer, Bovidae, Artiodactyla
Parameter 4 - Experimentally susceptible domestic species (or family/orders)
• Cattle, Bos taurus, Bovidae, Artiodactyla
• Goat, Capra hircus, Bovidae, Artiodactyla
• Sheep, Ovis aries, Bovidae, Artiodactyla
• Alpaca (Vicugna pacos) (Schulz et al., 2012)
• Llama (Lama glama), Camelidae, Artiodactyla
Reservoir animal species
Since in most outbreaks BT is a vector-borne disease (except for serotypes 25–27, which can be
directly transmitted), the level of viraemia and its duration are key factors for a host to be a reservoir.
Prolonged but not persistent cell-associated viraemia is characteristic of BTV infection of ruminants
(Barratt-Boyes and MacLachlan, 1995; MacLachlan, 2004), and plasma viraemia is transient and of
relatively low titre, while adult Culicoides become infected for life.
This prolonged blood cell-associated infection of ruminants is important, because it increases the
likelihood that feeding insect vectors will acquire infection, and prolonged infection also potentially
complicates the safe movement of animals between BTV-free and -infected regions. Although it is clear
that BTV infection of ruminants is prolonged but not persistent (MacLachlan, 2004; Melville et al.,
2004; White and Mecham, 2004; Lunt et al., 2006), the reported duration of viraemia in ruminants has
varied markedly between studies.
An animal species can be classiﬁed as reservoir for BTV if it maintains the virus in the ﬁeld, acting
as a source of infection, and further spread, in the presence of other favourable factors: climatic
conditions and related presence and abundance of vectors, density of susceptible wild and domestic
host population.
Recent studies indicate that at least for BTV-1–24 the duration of viraemia in BTV-infected
ruminants reﬂects in part the life span of circulating red blood cells that carry the virus, thus viraemia
is slightly longer in cattle than in sheep infected with the same strain of BTV as the life span of red
blood cells is somewhat longer in cattle than it is in sheep, (Bonneau et al., 2002). It is important to
note that although the virus is attached to red blood cells via its haemagglutinin activity, and its
genomic RNA can be detected by diagnostic molecular techniques (for example RT–PCR assays), it
progressively becomes more difﬁcult to recover infectious virus in cell cultures or other systems. After
the initial period of viraemia (and circulation of infectious virus) lasting 3–4 weeks, the level of
neutralising antibodies increases to the point where virus isolation is difﬁcult or not feasible. The
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animals involved can therefore be considered as non-infectious, even though viral genome RNA may
still be detectable in some animals for extended periods. Comparison of data obtained from prior
studies is further complicated by the fact that these studies have described infections with a variety of
BTV serotypes and strains, animals of different ages and breeds that were either naturally or
experimentally infected with BTV (by different routes of inoculation), and different methods of virus
isolation or detection (Singer et al., 2001). The virus inoculum used in each study is especially
important, not just because of the potential impact of genetic variations between strains and
serotypes, but also because of the biological properties of ﬁeld (wild-type) and laboratory-adapted
strains of BTV can be markedly different (Kirkland, 2004; Kirkland and Hawkes, 2004).
In the past decade, new serotypes (BTV-25, BTV-26, BTV-27 and related strains) have been
described (Hofmann et al., 2008; Maan et al., 2011c; Zientara et al., 2014; Savini et al., 2017). These
differ from the historical 24 serotypes, because they are characterised by causing asymptomatic
infections, at least for BTV-26 (Batten et al., 2014), they have longer viraemia, suggesting an
alternative mechanism of persistence in the host (BTV-25, Vogtlin et al., 2013) and use goats and
sheep as reservoir hosts (Batten et al., 2012, 2013a). They are therefore deﬁned in the current opinion
as ‘small ruminant-adapted strains’. Furthermore there is evidence that these novel strains cannot
infect (at least one) known vector species of biting midge, Culicoides sonorensis since do not infect a
C. sonoresis cell line, or colony-derived adult insects via an oral route (Pullinger et al., 2016). However,
there are no data concerning the ability of the small ruminant-adapted novel strains to infect European
vectors. These data suggest that, for at least for the novel serotypes, direct contact may be the
primary route of transmission.
Parameter 5 – Wild reservoir species (or family/orders)
In Table 3 below, further information on length of viraemia in the wild reservoir species for different
BTV serotypes is reported. Out of those species, red deer could be a possible wild reservoir of BTV in
the EU (EFSA AHAW Panel, 2017a).
Table 3: Summary outcomes of systematic review of experimental infections with BTV in wild
species (papers published up to January 2016)
Common
name
Species Family Order Ref BTV
serotype
Virus detection
(range of days)
Virus
isolation
RT-PCR
Alpaca Vicugna
pacos
Camelidae Artiodactyla Schulz et al. (2012) 8 2–6 2–35
(106)
American bison Bison bison Bovidae Artiodactyla Tessaro and Clavijo
(2001)
11 4–42
Camel Camelus
dromedarius
Camelidae Artiodactyla Batten et al. (2011) 1 7–8 5–68
Deer (Mule,
White-tailed
and Red deer)
Odocoileus
hemionus,
Odocoileus
virginianus,
Cervus
elaphus
Cervidae Artiodactyla Work et al. (1992),
Drolet et al. (2013),
Thomas and Trainer
(1970), Vosdingh
et al. (1968),
Lopez-Olvera et al.
(2010), Lorca-Oro
et al. (2012)
1, 8,
10, 17
2–28 1–112
Llama Lama
glama
Camelidae Artiodactyla Schulz et al. (2012) 8 2–6 2–35
(106)
Wapiti elk Cervus
canadensis
Cervidae Artiodactyla Murray and Trainer
(1970), Stott et al.
(1982)
8,11 2–10
(190 bone
marrow)
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Parameter 6 – Domestic reservoir species (or family/orders)
In a previous EFSA opinion, based on a systematic literature review, it was concluded that, in
general for all BTV serotypes, BTV nucleic acid can be detected by RT-PCR in the blood of infected
cattle and sheep for 4–5 months after the infection, and up to 2 months in goats, while infectious
virus in the blood can only be detected for up to 50 days in cattle and up to 30 days in small
ruminants in the majority of the cases (EFSA AHAW Panel, 2017a).
In Table 4 below, further information on length of viraemia in the three main domestic ruminant
species about different BTV serotypes is reported.
Table 4: Summary outcomes of systematic review of experimental infections with BTV in domestic
species (papers published up to January 2016)
Common
name
Species Ref
No of
Animals
BTV
serotype
Virus detection
(range of days)
Virus
isolation
RT-PCR
Cattle Bos
taurus
Anderson et al. (2014), Backx et al. (2009),
Barratt-Boyes and MacLachlan (1994),
Barratt-Boyes et al. (1995), Barros et al.
(2009), Bonneau et al. (2002), Bowen and
Howard (1984), Bowen et al. (1983), De la
Concha-Bermejillo et al. (1993), Darpel
et al. (2016), DeMaula et al. (2002), Ellis
et al. (1993), Groocock et al. (1983), Gu
et al. (2014), Gubbins et al. (2012), Hamers
et al. (2009a), Jochim et al. (1974), Luedke
et al. (1969), MacLachlan and Fuller (1986),
MacLachlan and Thompson (1985),
MacLachlan et al. (1994, 1984, 1987,
1990), Martinelle et al. (2011), Monaco
et al. (2004a,b,c), Odeon et al. (1999),
Parsonson et al. (1994, 1987a,b), Dal Pozzo
et al. (2009), Richards et al. (1988), Roeder
et al. (1991), Schlafer et al. (1990),
Van der Sluijs et al. (2012), Squire (1989),
Thomas et al. (1985), Waeckerlin et al.
(2010), Waldvogel et al. (1992a);
Waldvogel et al. (1992b), Whetter et al.
(1989)
350 1, 2, 4, 8,
10, 11, 17,
20
1–62 1–167
Goats Capra
hircus
Batten et al. (2014, 2012), Belbis et al.
(2013), Breard et al. (2011), Caporale et al.
(2014), Coetzee et al. (2013), Planzer et al.
(2011), Vogtlin et al. (2013)
12 4, 8, 25,
26
3–32 2–55
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3.3.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/Incidence
In the course of a BTV infection in a region, three fundamental steps can be distinguished
(Randolph and Rogers, 2010): introduction, establishment and spread in a geographical sense. A
fourth period may be seen after an outbreak, where, although there are still sources of infection, much
of the ruminant population may be immune and the number of new cases is very low. During this
period, the outbreak may become self limiting and can disappear. This may explain why many
outbreaks of BT caused by a single serotype last for 3 years. During these different stages, the
prevalence of infected animals in a region changes, since, upon introduction into a BTV-free region,
the prevalence in a geographical unit rises from zero to a maximum (plateau prevalence) and
subsequently drops again either to zero, in case the infection fades out, or to a level determined by
endemic infection in the region (Giovannini et al., 2004; Schaik et al., 2008; Santman-Berends et al.,
2010; EFSA AHAW Panel, 2017a). The value of the plateau prevalence depends on the density of
susceptible ruminants, the relative efﬁciency of transmission of the virus strain involved and the
Common
name
Species Ref
No of
Animals
BTV
serotype
Virus detection
(range of days)
Virus
isolation
RT-PCR
Sheep Ovis
aries
Anderson and Jensen (1969), Backx et al.
(2007), Batten et al. (2012), Bonneau et al.
(2002), Breard et al. (2015), Caporale et al.
(2014), Chaignat et al. (2009), Chand et al.
(2009), Channappanavar et al. (2012),
Darpel et al. (2016), DeMaula et al. (2002),
Dungu et al. (2008), Ellis et al. (1993),
Emidio et al. (2004), Enright and Osburn
(1980), Eschbaumer et al. (2010, 2009),
Feenstra et al. (2014), Flanagan et al.
(1982), Forman et al. (1989), van Gennip
et al. (2012), Ghalib et al. (1985), Goldsmit
et al. (1975), Gubbins et al. (2012),
Hamblin et al. (1998), Hamers et al.
(2009a,b), Hare et al. (1988), Jeggo et al.
(1987), Koumbati et al. (1999), Letchworth
and Appleton (1983), Luedke (1969),
Luedke et al. (1976, 1969), Lunt et al.
(2006), MacLachlan et al. (2008), Mahrt
and Osburn (1986), Matsuo et al. (2011),
McColl and Gould (1994), Moulin et al.
(2012), Nunamaker et al. (1992), Pages
et al. (2014), Pini (1976), Ramakrishnan
et al. (2006), Rasmussen et al. (2013),
Richards et al. (1988), Richardson et al.
(1985), Sanchez-Cordon et al. (2013),
Savini et al. (2007), Shad et al. (1997),
Singh et al. (2008), Van der Sluijs et al.
(2011, 2012, 2013a, 2013b), Squire (1989),
Stanislawek et al. (1996), Stott et al.
(1985), Tanya et al. (1992), Tessaro and
Clavijo (2001), Tomori (1980), Umeshappa
et al. (2011), Uren and George (1985),
Uren and Squire (1982), Veronesi et al.
(2010), Waeckerlin et al. (2010), Worwa
et al. (2010)
1,108 1, 3, 4, 7,
8,
9, 10, 11,
13,
14, 16, 17,
18, 2, 20,
21, 23, 25,
26
1–54 1–222
AHL assessment on bluetongue
www.efsa.europa.eu/efsajournal 23 EFSA Journal 2017;15(8):4957
density of active and competent vectors (Hartemink et al., 2009) and the contact pattern between
them. Whether the virus is able to establish an endemic infection in the area depends on the ability of
the virus to overwinter and the rate at which susceptible ruminants are re-introduced into the
population (vaccination reduces this rate).
The infection and serological prevalence values (virus and antibody prevalence) at herd and animal
level obtained from a SLR and from the MSs are reported in previous EFSA outputs (EFSA AHAW
Panel, 2017a), where information at serotype level is available only for BTV-8. In the epidemiological
phase 3 (infection population with prevalence having reached a plateau), the seroprevalence at animal
level ranged from 1.1% to 99% (median 38%) (data from SLR), and from 0.023% to 100% with
median value of 24% (data from MSs). The virus prevalence ranged from 0.1% to 9% with median
value of 1.6% (data from SLR).
Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
Disease severity may be inﬂuenced by factors such as the virus strain, host factors (e.g. level of
immunity (including colostral antibodies), to the same or to heterologous serotypes, general health,
genetic factors, age and possibly breed) and environmental stressors. Sheep are usually the most
severely affected domesticated species, and in endemic regions, they are often the only domesticated
animal with obvious clinical signs. Morbidity rates in sheep range from < 5% to 50–75% (or higher),
and are usually at their highest when the virus is ﬁrst introduced (CSFPH, 2015). Once a virus has
become endemic, morbidity may decrease to low levels (e.g. 1–2%), with very few deaths. The
introduction of an exotic strain into an endemic region may also result in a new outbreak of disease
with high levels of morbidity and mortality. Outbreaks are uncommon where a virus circulates
year-round. Other species such as cattle and goats can also be affected when a bluetongue virus is
introduced into a naive population. Cattle became ill during recent serotype 8 and 4 outbreaks in
Europe.
Information on different levels of morbidity for different BTV strains is shown in Table 1, based on
ADNS data since 1999. As shown, morbidity of BT can be very variable even within the same serotype,
but all ‘historical’ serotypes were categorised in the impact table as high virulent (pathogenicity score 5
and 6) at least for one strain. On the contrary, the novel small ruminant-adapted strains (belonging to
BTV-25, -26, -27) do not cause signiﬁcant clinical symptoms. In order to show this variability, the
boxplot displaying the distribution of the within-herd morbidity in sheep and cattle for as examples, the
outbreak of BTV-4 in 2014–2016 and BTV-8 in 2006–2009 is shown in Figures 1 and 2.
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This extreme high variability in morbidity and mortality rates is generally and globally recognised for
all ‘classical’ serotypes, as reported by the OIE both in the technical disease card on bluetongue:
‘Morbidity in sheep can reach 100% with mortality between 30% and 70% in more susceptible breeds;
mortality in wild deer and antelopes can reach 90%’. (OIE, 2013b), and in the OIE manual where it is
stated that the outcome of infection ranges from unapparent in the vast majority of infected animals,
especially wild African ruminants, cattle and goats, to serious or fatal in a proportion of infected sheep,
goats, deer and some wild ruminants, although higher incidence of clinical disease has been observed
in cattle infected with BVT-8 in Europe (OIE, 2017). Furthermore some breeds of sheep are more
susceptible to disease than others: clinical signs of disease in sheep vary markedly in severity,
inﬂuenced by the type or strain of the infecting virus, husbandry factors as well as by breed (OIE,
2017).
Even in endemic countries BTV epidemics supported by particularly favourable climatic and
environmental condition can cause extensive losses. For example, in India, BT caused death of
300,000 sheep and goats in Tamil Nadu during the monsoon season of 1997–1998 and repeated
epidemics were observed in the following years (Ranjan et al., 2015)
Also, the literature on BT outbreaks in Europe conﬁrms this characteristic of extreme variability of
the clinical outcome of BTV infection. Within the same sheep breed, or even within the same ﬂock,
Figure 1: Intraherd morbidity of BTV-4 in small ruminants and cattle in the epidemics 2014–2016
Figure 2: Intraherd morbidity of BTV-8 in small ruminants and cattle in the epidemics 2006–2009
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there may be considerable differences in the severity of the disease occurrence in individual animals.
Serotypes/strains of BTV with different degrees of virulence have been described in the literature For
example, the North European BTV-8 strains that spread since 2006 in northern Europe is considered
highly virulent, as it induced severe clinical disease in cattle and in naive sheep. On the other hand, it
is interesting to note that no clinical cases of disease were observed even in sheep when BTV-8
reached northern Italy and Sardinia a few years later (Caporale et al., 2014).
During the ﬁrst BTV-2 epidemics in Italy in 2000–2001 (Calistri et al., 2004a), in absence of any
vaccination intervention, approximately 263,000 diseased sheep and goats were reported (18%
morbidity) and 48,000 sheep and goats died (3% mortality). During the second BTV-2 epidemic in
2001–2002, approximately 251,000 diseased sheep and goats were reported (18% morbidity) and
73,000 sheep and goats died (5% mortality).
In the recent BT epidemic in south-east Europe linked to BTV-4, in Greece in 2014, a total of 2,895
outbreaks have been reported with morbidity rates of 11.0%, 2.0% and 3.5%, in sheep, goats and
cattle, respectively. However in ﬁeld investigations, a signiﬁcantly higher bluetongue morbidity rate
(27.5%) in sheep was reported (Vasileiou et al., 2016). In another survey on 15 sheep ﬂocks, the
average morbidity of BT in the sheep ﬂocks was estimated to be 15.3% (95% CI 6.8–23.8%) and the
average mortality and case fatality were 4.5% (95% CI 1.5–7.6%) and 32.0% (95% CI 18.1–42.9%),
respectively (Katsoulos et al., 2016). The BTV seroprevalence and the ratio of clinical manifestations-
to-infections determined in seven of these ﬂocks, were on average 36.5% (95% CI 15.7–57.3%) and
24.6% (95% C.I. 12.8–36.3 %), respectively (Katsoulos et al., 2016).
In Romania, in 2014, the overall observed morbidity rate considering the whole outbreak period
from August to December was 0.05% in cattle and 0.03% in sheep, but with peaks of 43% in cattle
and 3.8% in sheep at the beginning of the outbreak (Tilibașa et al., 2014). In Serbia, the same BTV-4
epidemics caused economic losses affecting sheep, cattle and goats with morbidity of 0.2%, 0.06%
and 0.03%, respectively. Recorded mortality in cattle, sheep and goats was 18.45% (n = 38), 48.10%
(n = 1,002) and 54.17% (n = 13), respectively (Djuric et al., 2017).
The same situation of variable clinical impact of BT has been observed in Spain, which has been
affected by several different BTV serotypes in the last 50 years. In the review by Diego et al. (2013),
who reviewed the history of BT epidemics in Spain since the 1960s, it was conﬁrmed that BT outbreaks
have shown variable clinical signs, morbidity and mortality. In the 1960s, morbidity in sheep due to
BTV-10 outbreak was 3.5% and mortality 2.6%. This serotype caused disease in approximately
180,000 animals in the Spanish epidemic. The outbreak of BTV-2 in Balearic Islands in 2,000 led to the
death of approximately 10,000 animals, due to the disease or stamping out, with a morbidity of 14.1%
and mortality of 7.8%. With the ﬁrst report of BTV-4 in 2004, which spread rapidly throughout
southern Spain, 332 outbreaks were reported but no clinical disease was observed in bovines, and low
morbidity and mortality were reported in sheep. Later on, in 2007, BTV-1 was detected which caused
an average mortality of 7%, and proven to be more virulent than BTV-4 for the Spanish sheep. In
2008, BTV-8 strain was detected for the ﬁrst time in northern Spain, which caused only mild clinical
disease in sheep, in contrast to the more serious disease observed elsewhere in northern Europe
(Diego et al., 2013).
For example, the outbreaks due to BTV-8 in sheep in the Netherlands in 2006 caused 7.7%
morbidity and 4.4% mortality (Elbers et al., 2008). In Germany, in the same epidemics, morbidity was
2.3% and 6.3%, mortality of 0.2% and 2.6%, and a case-fatality rate of 6.4% and 37.5% in 2006 and
13.1% and 41.5% in 2007, in cattle and sheep respectively.
Among wildlife, white-tailed deer, brocket deer and pronghorn antelope can be severely affected,
with morbidity rates reported to be as high as 100%. In Europe, red deer seem to be the most
important wildlife species; during BTV-8 outbreaks, more than half the red deer surveyed in some
areas were seropositive. A few seropositive dogs have been reported in the USA and a pair of Eurasian
Lynx died after becoming infected with BTV-8 after ingesting infected meat (Jauniaux et al., 2008).
Sanderson (2012) reported seropositivity to BTV-8 in the following ruminant species from European
zoos: yak (Bos grunniens), American Bison (Bison bison), European bison (Bison bonasus), blackbuck
(Antilope cervicapra), mouﬂon (Ovis orientalis), ibex (Capra ibex), Siberian ibex (Capra sibirica), musk
ox (Ovibos moschatus), alpaca (Lama pacos), Bactrian camel (Camelus bactrianus), fallow Deer
(Dama dama). In over 200 African ruminant species from European zoos, different level of
seropositivity was detected, although none of them showed clinical signs, being consistent with the
observation in the ﬁeld where indigenous antelope do not develop any clinical symptoms (Sanderson
et al., 2012).
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Mortality
Parameter 3 – Case-fatality rate
Information on different levels of mortality (number of deaths out of the total susceptible
population) and case-fatality rates (proportion of deaths out of infected cases) in different BTV strains
is shown in the Table 1, based on ADNS data since 1999 and in the above section on case-morbidity
rate when discussing literature ﬁndings on different BT outbreaks. The case-fatality is very variable,
even within the same serotype, and depending on the immune status of the host can vary dramatically
even with the same virus strain, but all ‘historical’ serotypes (BTV-1–9) were categorised in the impact
table as highly lethal above all for sheep (cattle and goats it is generally lower and may be negligible),
up to 100% (given the worst case, 95th percentile of the distribution) at least for one strain within the
same serotype. In contrast, the small ruminant adapted strains (BTV-25–30) are not considered to
cause any signiﬁcant clinical symptoms. BTV-16 has lower mortality rates during recent circulation in
southern Europe.
The case fatality rate is typically < 30%, can reach 50–90% in highly susceptible populations, and
decrease to very low levels once the virus has become endemic (CSFPH, 2015). Case-fatality can vary
with the strain of BTV, host species, immune status and breed infected. It has also been reported that
different populations of the same sheep breed from different regions can have different levels of
innate resistance to speciﬁc virus strains. Local sheep breeds can also show higher levels of resistance
to indigenous virus strains, but may be severely affected by introduced exotic strains. Mortality and
case fatality is likely to be highest when a strain of BTV reaches an area for the ﬁrst time.
An incursion in 2001 of BTV-2 into Corsica caused a mortality of 40% in unvaccinated sheep ﬂocks.
This was compared with 5.1% in vaccinated ﬂocks (Breard et al., 2004). More recently, in Corsica with
the outbreak of BTV-1 in 2013, morbidity and mortality rates on the day of notiﬁcation varied from 1%
to 80% and 0% to 11%, respectively, depending on the herds. (Sailleau et al., 2015).
Giovannini et al. (2004) reported a mortality rate among sheep and goats of 3.3% when BTV-2
occurred in Sardinia, Sicily and Calabria in 2000. The following year a more widespread epidemic
mainly due to BTV-9 was associated with a mortality of 5.2%.
A study from the Netherlands was based on ofﬁcial reports from farms to estimate the mortality in
cattle attributable to the BTV-8 epidemic in 2007 (Santman-Berends et al., 2011b). In conﬁrmed
infected herds, they reported a mortality rate ratio of between 1.2 (95% CI 1.1–1.3), 1.3 (95% CI
1.1–1.5), and 1.4 (95% CI 1.2–1.6) for age categories < 3 days, 3 days–1 year and > 1 year,
respectively. This estimate was based on a comparison between BTV-8 affected months and
non-affected months in the same herd adjusted for relevant confounders.
In Germany, BTV-8 in 2006–2007 led to a case-fatality rate of 37–41% in sheep, 6–13% in cattle
and 26% in goats (Conraths et al., 2009).
In wild animals, Sanderson (2012) reported mortality linked to BTV infection in ruminant species
from European zoos, same species as indicated in section about case-morbidity. Furthermore, in the
US, Thorne et al. (1988) reported 2.3% mortality in pronghorn (Antilocapra americana), and less than
1% in mule deer (Odocoileus hemionus) and white-tailed deer (Odocoileus virginianus).
3.3.1.3. Article 7(a)(iii) The zoonotic character of the disease
Humans are not susceptible to bluetongue virus.
3.3.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Not applicable, since antiviral treatment is not used against BTV as feasible control option.
3.3.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
There are currently 27 conﬁrmed serotypes of BTV, with additional strains that have been identiﬁed
that may represent a total of > 30 serotypes (Maan et al., 2011c, 2012a,b; Zientara et al., 2014; Savini
et al., 2017). The global distribution of these serotypes is not uniform, rather different constellations of
BTV serotypes are disseminated by different species of Culicoides vector in relatively distinct global
ecosystems (Gibbs and Greiner, 1994; Daniels et al., 2004; Maclachlan and Osburn, 2006; Tabachnick,
2004). BTV serotypes 25–27 have been identiﬁed only recently as infecting small ruminants in Europe
and the Middle East, and serotype 25 (BTV-25; also known as Toggenburg orbivirus) has yet to be
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isolated although it has been sequenced (Maan et al., 2011c; Zientara et al., 2015; 36). While the
epidemiologic features of BTV-1–24 infections are similar in that they are all spread predominantly by
biting Culicoides midges, there is uncertainty regarding the role of Culicoides midges (if any) in the
transmission of BTV-25, BTV-26 and BTV-27 (Vogtlin et al., 2013; Batten et al., 2014). Duration of
viraemia in BTV-25 infected goats also is markedly more prolonged than that in livestock infected with
other BTV serotypes (Singer et al., 2001; Verwoerd and Erasmus, 2004; Maclachlan et al., 2009; OIE,
2013a; Vogtlin et al., 2013).
For those serotypes (1–24) of BTV which use haematophagous vectors for transmission, the level of
viraemia and its duration are key factors for virus transmission. Studies with recent European isolates of
BTV serotypes 2, 4, 9 and 16 established viraemia periods of 14–45 days in experimentally infected
sheep (longest in sheep inoculated with serotype 2), up to 31 days in goats inoculated with serotype 2
and up to 19 days in cattle inoculated with serotype 2 or 4 (Savini et al., 2001; Monaco et al., 2006;
Savini et al., 2006a,b). Viraemia persisted in sheep vaccinated with live attenuated strains of BTV-2, -4,
-9 and -16 (including multivalent constructs) for up to 24 days, whereas viraemia in cattle inoculated
with the same live attenuated vaccine viruses persisted for up to 78 days (Monaco et al., 2004a,b,
2006; Savini et al., 2004a,b, 2005a,b, 2006c). The recent output by EFSA showed that BTV nucleic acid
can be detected by RT-PCR in the blood of infected cattle and sheep till 4–5 months after the infection,
and up to 2 months in goats, while infectious virus in the blood can only be detected for up to 50 days
in cattle and up to 30 days in small ruminants in the majority of the cases (EFSA AHAW Panel, 2017a).
This approximately 60-day infective period is considerably shorter than the interval (up to 7 months
or even longer) after infection of ruminants when BTV nucleic acid may be detected in ruminant blood
by appropriate prescribed BTV-speciﬁc PCR assays (MacLachlan et al., 1994; Bonneau et al., 2002).
Since PCR detects BTV RNA but cannot distinguish between inactivated and infectious virus, the PCR
assay is overly sensitive for identifying animal that still represent a source of BTV infection, but is
useful for detecting those animals that have been infected, but are no longer a source of infection, for
surveillance purposes. A 60-day infective period is more reﬂective of the maximal period when
ruminants are thought to be infectious to competent insect vectors, although in reality the duration of
this ‘infectivity’ is also affected by the level of viraemia in the host (which determines the amount of
virus ingested by the insect and consequently the percentage of insects that become infected) which
gradually declines, and consequently, the highest probability ‘infectious period’ is markedly shorter
than 60 days, in the vast majority of infected ruminants. During this period, the infected host will
normally develop a neutralising antibody response, which in itself is considered likely to reduce the
possibility of circulating virus being infectious. However, authentic instances of individual animals with
viraemias of greater than 60 days have been described on occasion in naturally infected cattle (Owen
et al., 1965; Melville et al., 1996), and may be a feature of infection with certain strains of speciﬁc BTV
serotypes (e.g. serotypes 15 and 16) and inoculation with certain live attenuated vaccine virus strains
(Monaco et al., 2004a,b,c).
The OIE accepted and adopted an infective period of 60 days for BTV-infected ruminants, after due
discussion and consideration of all published data. Prolonged viraemia has also been reported in other
species, such as red deer (Cervus elaphus). The epidemiology of BTV-25, BTV-26 and BTV-27 infection
of goats appears to be different than that of the other serotypes (BTV-1–24) and may not involve
Culicoides midges (Vogtlin et al., 2013). Recent studies also suggest direct contact transmission of
BTV-26, likely by aerosol, between goats (Batten et al., 2014). In one report, serotype 25 viral RNA
was found for at least 2 years in goats, and the blood of some animals was infectious at
12–19 months (Vogtlin et al., 2013).
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
BTV can remain viable in infected tissue or blood samples for many years when stored refrigerated at
4°C or frozen at 70°C (Parsonson and McColl, 1995). In a systematic review of literature on vector-
borne pathogens, only one reference was found reporting survival times for BTV (Parsonson and McColl,
1995). In this study, sheep were inoculated with BTV serotypes 1, 11, 17 and 23, and samples were
collected at necropsy and stored at 70°C for 1,277 or 5,110 days. Infectious virus samples have been
stored and recovered from the orbivirus reference collection5 after 30 years at 80°C.
5 http://www.reoviridae.org/dsRNA_virus_proteins/ReoID/virus-nos-by-country.htm
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The recent EFSA output on BT showed that the BTV presence has been demonstrated in different
organs, including lymphoid tissue, skin and reproductive organs. The maximum duration of the
presence of BTV is registered in the spleen up to 40 days for infectious virus and up to 3 months for
its nucleic acid (EFSA AHAW Panel, 2017a).
In a recent paper submitted for publication (Puggioni et al., 2016), a BTV-1 infected blood sample
collected from an ewe with BT clinical signs during the 2006 Sardinia outbreak and stored in the fridge
at + 4°C, was able to cause clinical signs when inoculated in a ram 10 years later.
3.3.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans routes of
transmission
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
The usual route of BTV (1–24 serotypes) transmission to its animal (ruminant) hosts is via the bites
of virus-infected haematophagous Culicoides midges that act as biological vectors of the virus (Gibbs
and Greiner, 1994; Nevill, 1971; Mellor et al., 2000; Carpenter et al., 2013). Vector midges play a
crucial role to the natural epidemiology and spread of BTV. Here below the main routes of transmission
are described:
Vector midges (Culicoides spp.) can ﬂy short distances of 1–2 km, but they can be blown much
further by wind. Long distance spread of BTV from endemic regions to adjacent uninfected areas can
occur via the wind-borne dissemination of virus-infected midges, especially over water (Sedda et al.,
2012; Burgin et al., 2013). Thus, novel strains of BTV regularly are introduced by windborne midges
from Indonesia to the ‘Top End’ of Australia, and into Mediterranean Europe from North Africa (Calistri
et al., 2004a; Lorusso et al., 2013a; Eagles et al., 2014). Infected midges were likely responsible for the
spread of BTV-16 from Italy to Croatia (Listes et al., 2009), from Sardinia to Corsica (BTV-2 in 2000,
BTV-4 in 2003, BTV-16 in 2004, BTV-1 in 2013) and BTV-8 from mainland Europe to the UK in 2007
(Gloster et al., 2010; Szmaragd et al., 2010). Similarly, recent incursions of novel serotypes of BTV into
the south-eastern United States are perhaps the result of spread by windborne midges carrying viruses
that circulate in the Caribbean Basin (Johnson, 2007; Gibbs et al., 2008; Maclachlan, 2011).
The movement of BTV-infected animals can be responsible for translocation of BTV, however,
such occurrences are only important if the local vector population within the receiving region is able to
efﬁciently acquire and transmit the introduced virus. For example, a novel strain of BTV-2 that recently
appeared in California is closely related to viruses from Florida, suggesting this virus was translocated
across the continental United States by animal movement and then spread by vectors in California
(Maclachlan et al., 2013). Similarly, the spread of BTV-8 from France to Italy in 2007–2008 were likely
due to movement of infected cattle (Giovannini et al., 2008), as well as the spread of BTV-14 from
Poland to Spain (ref), the spread of BTV-1 from south-west France to Britanny (Defra, 2008), and the
import of pregnant cattle to Ireland from the Netherlands (Menzies et al., 2008).
Vector-independent transmission of BTV clearly can occur, although its signiﬁcance is largely
unknown. The epidemiology of BTV-25, 26 and 27 infection of goats appears to be different than that
of the other serotypes (BTV-1–24) and may not involve Culicoides midges (Vogtlin et al., 2013). In
fact, BTV-25 and BTV-27 do not replicate in Culicoides cells and the viraemia in infected animals is
longer than in BTV-1–24.
Recent studies also demonstrated direct contact transmission of BTV-26, likely by aerosol,
between goats (Batten et al., 2014). In fact, although the kinetics of BTV-26 infection in sheep and
goats are similar to those of BTV-25, the virus can be horizontally transmitted to uninfected, in-contact
goats which subsequently seroconvert (Batten et al., 2013a, 2014). This indicated that unlike BTV-25,
BTV-26 can be transmitted horizontally by direct contact and replicates in mammalian cells (BHK-21,
BSR and Vero cells) in vitro, but does not replicate in KC cells.
In a study conducted in dromedaries in Mauritania slaughterhouse, BTV-26 neutralising antibodies
were found in a high number of animals conﬁrming that horizontal transmission may have occurred in
this case at the slaughterhouse, where animals are gathered together for several days before
slaughtering (Lorusso et al., 2016). There is also evidence that BTV-26 cannot infect at least one
species of midges known to be a BTV vector (Culicoides sonorensis) suggesting that an alternative
horizontal transmission mechanism may be essential for this virus (Pullinger et al., 2016).
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BTV-27 has been observed that during an experimental infection, a control in-contact goat was
infected by direct transmission (Breard et al., in preparation). In ﬁeld conditions, the spread of BTV-27
seems to be limited in space, differently than the one by vector spread (Breard et al., in preparation).
Oral BTV infection of both ruminant livestock and wild or zoo carnivores has been described,
including infection of calves via the feeding of infective colostrum (Alexander et al., 1994; Mayo et al.,
2010) and experimentally via cultured viruses or urine from an experimentally infected sheep. At least
some BT strains (including members of serotypes 1, 2 and 8) can be transmitted directly between
ruminants in close contact (van der Sluijs et al., 2011; Rasmussen et al., 2013; van der Sluijs et al.,
2013b). The mechanisms of contact transmission are still uncertain. Suggestions have included shared
feed and water troughs, contamination of wounds with blood during ﬁghting among red deer, and
contact with infected placentas in a case in cattle. This is a newly recognised route, and is generally
thought to be of little epidemiological signiﬁcance compared to transmission by midges for the
expansion of an outbreak, although the long duration of pregnancy in cattle suggests that vertical
transmission and the release of virus at birth may provide an important overwintering route and may
therefore be epidemiologically signiﬁcant, even if relatively infrequent. Seropositive dogs, cats and wild
carnivores in Africa were thought to have eaten tissues from infected animals, and Eurasian lynx in a
zoo that died after infection with BTV-8 had been fed ruminant fetuses and stillborn animals from
outbreak areas. However, seropositive dogs in Morocco had not been fed raw diets, suggesting that
they may have been infected by Culicoides.
Contamination of biological products, notably those that utilise fetal bovine serum, is also well
described as, for example, in canine and cattle vaccines (Akita et al., 1994). Primary ruminant cell lines
may also be a source of contamination, such as lamb testis cells contaminated with BTV-28 (Bumbarov
et al., 2016).
Vertical transmission of BTV in animals certainly does occur, notably with live attenuated vaccine
strains of BTV and European BTV-8, but this route is considered unlikely to be important to the initial
expansion of natural BTV outbreaks (Verwoerd and Erasmus, 2004; Maclachlan et al., 2009;
Saegerman et al., 2011; van der Sluijs et al., 2014; EFSA AHAW Panel, 2017a). Some of these animals
can be born infected and may allow BTV to overwinter, with the potential to introduce the virus to new
areas if the dam is transported. Transplacental transmission (TPT) has been demonstrated in dogs, at
least for serotype 11 (Akita et al., 1994). For BTV serotypes other than BTV-8, TPT was experimentally
demonstrated for BTV-2 in sheep and BTV-11 in cattle and North American elk (EFSA AHAW Panel,
2017a).
BTV-8 has been detected in the semen of naturally infected bulls by both PCR and virus
isolation, indicating that BTV-8 may contaminate semen in a similar way to tissue culture-passaged
viruses. Further work is required to investigate the duration of the BTV-8 presence in semen. Apart
from BTV-8, ﬁeld/wild strains of BTV have only been identiﬁed in the semen of older bulls, most likely
due to blood contamination. It has been demonstrated that females inseminated with cell-culture-
adapted BTV-contaminated semen can become infected. The vast majority of evidence shows that
isolation of BTV in semen coincides with the viraemic period in the bull/ram. However, one study
showed that a tissue culture-passaged strain of BTV-1 was detected in semen for approximately 10
days beyond the period of detectable viraemia in the bull. In general, recipient animals have not
shown evidence of infection after receiving embryos from infected donors, apart from one study with
BTV-11 in which the recipient heifers sero-converted.
In some circumstances, the human role in mediating the introduction of BTV vaccine
viruses, rather than animal movement has been suggested (De Clercq et al., 2009; Reviriego Gordejo,
2013). For example, the recent appearance of at least three (BTV-6, BTV-11 and BTV-14) different
South African live-attenuated BTV vaccine strains among livestock in Europe (most recently BTV-14 in
western Russia, Poland and Lithuania) has been recorded. Interestingly, live-attenuated vaccine strains
of BTV-6 and BTV-11 ﬁrst appeared in the same general region of northern Europe as did BTV-8 in
2006 (Enserink, 2006), again suggesting an as yet unexplained anthropogenic phenomenon. Similarly,
in India, strains of BTV-2 and -10 that are genetically similar or identical to live attenuated vaccine
viruses used elsewhere in the world have also been identiﬁed as infecting local livestock, raising
further concerns regarding the unauthorised international movement of vaccine viruses (Maan et al.,
2012a,b). Bluetongue virus can also be spread mechanically on surgical equipment and needles
(Darpel et al., 2016).
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Speed of transmission
As in the methodology opinion, transmission/transmissibility is described by two parameters,
incidence and transmission rate (EFSA, 2007).
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
Information on different levels of incidence for different BTV strains/serotypes is shown in Table 1,
based on ADNS data since 1999. The observed incidence is very variable, even within the same
serotype, but all ‘historical’ serotypes were categorised in the impact table as high or medium
transmissibility capacity at least for one strain (with the exception of BTV-16); on the contrary, the
routes of spread of goat strains are not totally clariﬁed, thus even the speed of spread is not known
but supposedly to be low.
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
A large number of heterogeneities related to vectors hosts and the environment inﬂuence both
spatial and temporal variation in R0, for example, the distribution of ruminant and vector species, and
regional differences in environmental factors, in particular, temperature (Anderson and May, 1991).
Although full risk assessment needs to take these factors into account and produce spatiotemporal
maps for R0, transmission models often inevitably ignored them. A recent EFSA output showed that R0
for BT exceed the value of 1 for temperatures ranging from 9.1 (in case of 20 Culicoides caught) to
11.5°C (in relation to ﬁve Culicoides caught), thus roughly conﬁrming possible thresholds around 10°C
for disease transmission (EFSA AHAW Panel, 2017a,b,c).
Although combining data of many serotypes for estimating some parameters (duration of host
viraemia, extrinsic incubation period) there may be differences among serotypes and, in particular,
interactions between host, virus and vector, which inﬂuence the ability of BTV to invade a host
population. For example, BTV- 2, -9 and -16 have all been introduced to Europe, but have not
extended much beyond the northern rim of the Mediterranean basin (Mellor and Wittmann, 2002;
Purse et al., 2005; Lorusso et al., 2014), while BTV-8 has appeared and spread in northern Europe
(Elbers et al., 2007), and BTV-1 spread right though Iberia into central France. This is showed also in
the impact table (Section 3.3), according to the spread capability to other episystems, which occurs
only for BTV-1, 4 and 8.
Uncertainty and sensitivity analyses based on Latin hypercube sampling and partial rank correlation
coefﬁcients identiﬁed temperature, the probability of transmission from host to vector and the
vector-to-host ratio as being most important in determining the magnitude of R0. The importance of
temperature reﬂects the fact that it inﬂuences many processes involved in the transmission of BTV
and, in particular, the biting rate, the extrinsic incubation period and the vector mortality rate (Gubbins
et al., 2008). The risk is greatest when the temperature is between 15°C and 25°C. At lower
temperatures, BTV is unable to replicate to transmissible levels, while at higher temperatures the
vector is less likely to survive for long enough to complete the extrinsic incubation period. Temperature
appears to be the main factor when basic reproduction numbers were applied to determine the vector
seasonal period in Austria. R0 above one was found between June and August except in the
mountainous regions of the Alps, at altitude where the midges are absent. The highest values coincide
with the locations of conﬁrmed BTV cases (Brugger and Rubel, 2013).
Although sophisticated airborne and ecological models may be beneﬁcial, sometimes relatively
simple analyses of basic epidemiological data can be more appropriate. In Italy, for example, a quite
uncomplicated risk assessment based on animal movement data allowed for identifying the areas at
risk for BTV-8 virus introduction (Giovannini et al., 2008). This shows that the general approach of
parsimony in the model complexity should always be followed (Calistri et al., 2013).
As reported in Table 1, there are some extreme situations, like the case of BTV-16, for which a very
limited transmission rate can be considered. Despite the absence of any vaccination against this
serotype and speciﬁc movement control policies, BTV-16 virus circulation was quite limited in few
geographical areas of Italy. The reasons behind the limited spread of this serotype are not fully clear
(Lorusso et al., 2013b).
De Koeijer et al. (2011) estimated different R0 values around 4 for the second half of the summer,
and falling below 1 by autumn for Germany, Belgium and the Netherlands related to the BTV-8
epidemic in 2006, conﬁrming the effects of host and vector variables to the speed of transmission of
the disease. Obviously, the speed of transmission is strongly inﬂuenced by the vector abundance and,
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therefore, by the local climatic conditions. Napp et al. (2016) estimated the case-reproduction ratio
(Rt) for the BTV-1 spread in Andalusia in 2007, resulting in values ranging from 4.6 in July, to 2.2 in
August, and below 1 in September (0.8) and October (0.02).
The expected level of vector transmission of some vector-borne diseases addressed in previous
EFSA output (EFSA AHAW Panel, 2017c) including BT, epizootic haemorrhagic disease virus (EHDV),
Palyam virus (KASV), BTV and equine encephalosis virus (EEV) is considered high in the EU, with R0
values between 3 and 10. Several factors are contributing to these high R0 values, such as the long
infectious periods in the host reported in experimental infections (e.g. medians of 17.5, 16.5, 21.3 and
16.5 dpi for EHDV, KASV, BTV and EEV, respectively). Further, the high numbers of the vectors per
hosts estimated (average of 20 vectors per host), the high biting rate (0.51 on average) contributed to
the high R0 values.
3.3.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, and, where the disease is not present in the Union, the risk of its
introduction into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in EU
In Figures 3 and 4, a map shows where BTV has been present in the EU in 2016–2017.
Figure 3: BTV serotypes reported to ADNS in the EU in 2016
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Temporal maps for each year showing the distribution of BTV serotypes in EU since 1999 until 2015
are shown in the Annex A to the present opinion.
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
Traditionally, the virus was present in a geographic band between the latitudes 40°N and 35°S
where its vectors, certain species of biting midges, were living (Rodrıguez-Sanchez et al., 2008;
Vellema, 2008; Wilson and Mellor, 2009). In North America, Europe and China, the virus spread even
further, up to 50°N (Mellor et al., 2000; Agren et al., 2010). Endemic areas exist in Africa, Europe, the
Middle East, North and South America and Asia, as well as on numerous islands (e.g. Australia, the
South Paciﬁc, the Caribbean and the Mediterranean). Multiple serotypes can be found in many regions.
The recent EFSA output on BTV showed that some Culicoides species, in some geographical areas
in Europe or during years with mild winter temperatures, i.e. are active throughout the year, thus
allowing BTV overwintering, as the example of serotype 8 virus that overwintered for multiple years in
central and northern Europe. However, there are periods of the year when the abundance of the
Culicoides vector species is extremely low, mainly coinciding with winter low to very low temperatures,
in particular in northern Europe. Long-standing practical experience demonstrates that transmission of
BTV is substantially reduced or halted during these periods.
Historically, Europe has experienced only sporadic incursions of BT, involving a single virus serotype
on each occasion (Mellor and Boorman, 1995). However, since 1998, BTV spread northwards into the
Mediterranean Basin, where seven BTV serotypes (1, 2, 4, 8, 9, 16 and 27) have been identiﬁed
(Purse et al., 2005). In the summer of 2006, for the ﬁrst time, the BTV has crossed latitude 50°N and
BT outbreaks caused by BTV-8 occurred in north-western Europe: the Netherlands, Belgium, Germany,
France and Luxembourg (Wilson and Mellor, 2008). In 2007–2008, the BT situation changed for the
worse, BTV-8 spread to the other regions of Europe and the number of outbreaks increased rapidly.
Additionally, two new BTV serotypes, BTV-11 and BTV-6, were detected (Wilson and Mellor, 2009). A
new virus, similar to BTV, and infecting goats was discovered in Switzerland in early 2008. It was
named Toggenburg orbivirus (Hofmann et al., 2008), and is a so far unknown orbivirus with low
pathogenicity and a potential BTV-25 (Hofmann et al., 2008; Chaignat et al., 2009).
Figure 4: BTV serotypes currently reported to ADNS in the EU in 2017 up to April
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BTV-2 and BTV-4 were eradicated from territories such as the Balearic Islands merely using
vaccination. However, the implementation of BT compulsory vaccination programmes in Europe
resulted in a massive reduction of BTV-8 cases. BTV was eradicated from central (partially) and
northern Europe; however, it is still circulating in some regions of central, southern and south-eastern
Europe. In 2012, BTV-4 and BTV-1 were present in Sardinia. In 2013, disease caused by BTV-1 was
spreading extensively over the territory of Italy (Sardinia, Sicily and mainland Italy). At the beginning
of 2014, the same BTV serotype has been isolated in Corsica (France). Moreover, BTV-1 cases were
noticed in the west Spain, outbreaks caused by BTV-4 in south Spain (Andalusia) and in the region of
Algarve in Portugal. In 2014, outbreaks of BTV-4 have been conﬁrmed in Greece (Peloponnese and
Evros regions). In July, the ﬁrst outbreak of BTV-4 was also reported at the south Bulgaria and from
there it spread to Bulgaria, Romania and all Balkan countries and southern Italy. In 2015, BTV-4
continued circulating in the Balkan Peninsula and Italy. In the same year BTV-8 re-emerged in France.
The current BTV circulation in Europe is displayed in Figure 3 and 4.
Regarding the epidemiological status of MS in relation to BT, it has to be said that the status could
be related to the occurrence of a single or multiple serotypes. According to the recent history of BT in
Europe, it is reasonable to say that BT is endemic in the countries of southern and eastern Europe.
BTV-8 is likely endemic in France. In the other countries of central and northern Europe, BT is
epidemic, although it is sporadic in the countries of the Scandinavian Peninsula and the UK.
Risk of introduction
The disease was introduced and already circulating in the EU.
Gerbier et al. (2008) estimated, from the epidemic in the northern part of western Europe, the rate
of BTV-8 spread after introduction into a na€ıve population at 15 km/week. However, Calistri et al.
(2004b) estimated the rate for BTV-2 in Sardinia at 30 km/week. Spread of BTV-infected vectors by air
across open water may even be beyond 30 km, as shown by the incursion of BTV into the UK (Gloster
et al., 2010). Moreover, Ducheyne et al. (2007) reported that windborne-spread of BTV-infected
vectors over sea may be possible for a distance of up to 750 km. However, spread over such a long
distance across land has never been published. Hendrickx et al. (2008) estimated that, in 2006, 50%
of the spread from an infected farm in Belgium took place within a 5 km radius and 95% within a
30 km radius. Using a different model, De Koeijer et al. (2011) estimated that 85% of the secondary
infections of BTV-8 took place within a 15-km radius of an infected farm. However, Szmaragd et al.
(2010) predicted even more localised spread than the De Koeijer et al. model. Both studies used the
same outbreak data set, including comparable assumptions on data, but assuming different spatial
transmission kernels (probability of infection as a function of the distance to an infectious source)
during model ﬁtting. This likely explains the detailed differences between derived spreading distances.
Nevertheless, the results of both studies suggest a local to intermediate spatial transmission. Taking
the information above into account (and assuming that infection starts in the centre of the grid)
means that the currently deﬁned geographical unit for monitoring and surveillance (45 9 45 km)
covers spatial spread of BTV infection of a few weeks. According to Reynolds et al. (2006), local
spread of BTV is mostly caused by active movements of the vectors themselves in all directions and is
rather symmetric, while the medium and long distance spread is caused by windborne movement of
vectors and animal movements and may follow a rather asymmetric pattern. Although increasing the
size of the zone considered to be infected might give more protection to surrounding free zones,
results from De Koeijer et al. (2011) suggest that doing this increases the amount of long distance
spread of BTV within the zone considered to be infected.
3.3.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
Virus detection
Various techniques have been used to detect the presence of the virus, antigen or viral RNA.
The most commonly used were: real time RT-PCR, conventional RT-PCR on agarose gel, capture
enzyme-linked immunosorbent assay (ELISA), viral isolation from embryonated chicken eggs and viral
isolation from mammal or insect cells. Traditional RT-PCR and real-time RT-PCR assays provide a versatile
system able to give information on orbivirus serogroup and serotype within a few hours. They are also
highly sensitive and capable of detecting very low concentrations of viral RNA. In addition, real-time
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assays are able to quantify the viral genome. Due to all these advantages, in most laboratories, these
new techniques are preferred to classical viral detection and identiﬁcation techniques, which require
three to four weeks to be completed. However, RT-PCRs are actually not able to distinguish whether the
RNA detected in the animal is part of an infectious virus or just RNA of degraded or neutralised virus that
is no longer able to infect the vector. The classical virus isolation technique (inoculation of embryonated
chicken eggs/mammal cells or insect cells/mammal cells), or transmission to another naive host are still
the only methods able to reveal the presence of infectious virus in an animal. Several studies have
conﬁrmed that, at least for some BTV serotypes, RNA could be detected in the blood longer than
infectious virus (MacLachlan et al., 1994; Singer et al., 2001; Bonneau et al., 2002; Di Gialleonardo
et al., 2011). The sensitivity of the RT-PCR in determining BTV circulation is dependent on the duration
of viral RNA persistence in the blood of the host. Based on the detection of BTV RNA in cattle for months
following infection (Bonneau et al., 2002; Di Gialleonardo et al., 2011), real-time RT-PCR could be
considered a valid and sensitive method for determining BTV circulation in cattle.
Both the live and inactivated vaccines recently deployed in Europe generate an immune response to
all of the BTV proteins. It has not therefore been possible to develop an effective serological assay to
distinguish infected from vaccinated animals (DIVA). The real-time PCR assay does not detect
inactivated vaccines for signiﬁcant periods post-inoculation, and has therefore been used as a DIVA
assay to allow continued surveillance during recent vaccination campaigns in Europe.
Antibody detection
Several techniques can be used to detect the presence of BTV-speciﬁc humoral antibodies in animals
which have either been infected with BTV or vaccinated against the virus. The methods enabling the
detection of BTV serogroup-speciﬁc antibodies in the serum and milk of infected animals most
commonly used are: competitive ELISA (c-ELISA), milk ELISA and for detection of serotype speciﬁc
antibodies, micromethod plate seroneutralisation (SN). The OIE has prescribed the competitive ELISA
(c-ELISA) serological test for bluetongue diagnosis for international trade. Over time, the accuracy of
this assay has been progressively improved through the use of antigens obtained from recombinant
structural proteins of BTV. The competitive ELISA, using direct antibodies against the VP7 protein that is
common to all BTV serotypes, detects the presence of antibodies to all 27 BTV serotypes. The technique
is highly sensitive and speciﬁc, with its speciﬁcity being due to the use of a monoclonal antibody speciﬁc
for VP7, the protein that distinguishes the BT serogroup from other Orbivirus species/serogroups. It is
able to determine the presence of antibodies no matter which serotype the BTV strain belongs to, and
represents the preferred method to determine and monitor BTV circulation, since it is cheap, sensitive
and speciﬁc. However, in cases where the population is vaccinated, it cannot be used to identify
infections, unless unvaccinated sentinels are tested as well. Although some kits have been developed
(see, for example, Barros et al., 2009), no serological DIVA tests for discriminating BTV-infected from
vaccinated animals are at the moment commercially available.
Milk ELISAs have also been developed that successfully assess the antibody status of animals with
respect to BTV infection. The advantage of these tests is that they can be used on bulk milk samples,
which has the obvious beneﬁt of testing groups of animals in one step, avoiding the need for blood
sampling (Kramps et al., 2007). Its speciﬁcity was recently improved by precipitating the milk protein
prior to carrying out the ELISA (Chaignat et al., 2009). However, once vaccines have been used a
persistent positive signal from vaccinated animals may reduce the value of these assays for surveillance.
As ELISAs are not able to distinguish between BTV serotypes, in areas where more than one
serotype has been circulating, the serum neutralisation assay is needed to determine the prevalence of
each BTV serotype. Serum neutralisation (SN) is the only serological method so far able to determine
the viral serotype responsible for the infection (serotype-speciﬁc test). Serotype identiﬁcation is
feasible by RT-PCR.
Control tools
Control of BT is attempted using either preventive (prophylactic) or therapeutic strategies
(Verwoerd and Erasmus, 2004; Papadopoulas et al., 2009; Maclachlan and Mayo, 2013; Zientara and
Sanchez-Vizcaino, 2013). Treatment of BT-affected ruminants is often unrewarding and logistically
challenging during outbreaks as it involves only nonspeciﬁc supportive and nursing care. Prevention of
BT and/or BTV infection of ungulates can be achieved either by protecting animals from insect attack
or prophylactic immunisation (vaccination). Elimination of Culicoides midges from the environment is
not practical generally, particularly in extensive pastoral settings. However, housing animals in
protected buildings during the peak of activity (dusk, early evening) to minimise exposure to biting
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midges can be beneﬁcial for vector species that exhibit strictly outdoor (exophagy) feeding behaviour,
but less so with those species that exhibit indoor (endophagy) feeding behaviour. Especially valuable
animals can be housed in vector-protected establishments to prevent any contact with vector midges
with 96% of efﬁcacy (EFSA AHAW Panel, 2017a) during outbreaks, or treated with repellents to
minimise the likelihood of vector attack. Vaccination is central to prevention of BT in many endemic areas,
and also to the response to incursions of the disease into previously unaffected regions (Verwoerd and
Erasmus, 2004; Savini et al., 2008). Zientara et al., 2010; McVey and Maclachlan, 2015).
3.3.2. Article 7(b) The impact of diseases
3.3.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
As shown in Section 3.3.1.7, the MSs where BTV is currently present are France, Italy, Spain,
Portugal, Croatia (Figures 3 and 4).
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
Losses due to any livestock disease may be classiﬁed as losses in production (direct losses),
expenditure and lost revenue (indirect losses) (Rushton, 2009). In case of BT in Europe, most studies
on the estimation of direct losses on production due to the disease impact are related to the epidemic
of BTV-8 occurrence in 2006–2008 in northern Europe. For the other serotypes, an estimation of the
direct losses can be derived by the morbidity and mortality rates (see Table 1). The impact of BT in
endemic situations appears to be relatively small and is dominated by the impacts on ﬂock and herd
fertility as well as vaccination. There are issues with regard the adoption of improved breeds and there
is evidence that where new and more productive breeds are incorporated into livestock systems BT
becomes more important. In this situation, the major costs is linked to the management of animal
vaccination for control and prevention of the disease (see Section 3.3.5).
In epidemic situations, the impacts are much more diffuse. First, there are na€ıve populations of
animals and the possibility of deaths of older more valuable animals is relevant. Fertility issues also
cause problems, particularly in systems where even small losses in calf, lamb or kid production can
affect the economic viability of a system. There are also well reported losses of milk production.
However, the largest and most serious impact with BT in epidemic situations is related to the reactions
to the presence and risk of the disease. Signiﬁcant resources are spent on new vaccines, and serious
restrictions are placed on animal movements. There are also impacts on markets. In short, the
reaction to the disease is usually large and perhaps in hindsight far greater than the production losses
usually caused by the disease itself. More details have been given in Section 3.3.5. In the epidemic
situation, the net costs depend on the virulence of the strain responsible of the incursion. It could be
much higher, as for the BTV-8 epidemic of 2006–2008, but also irrelevant as for the incursion of
BTV-11 or BTV-6. Most information is available for BTV-8 epidemic in 2006–2009 in northern Europe.
For BTV-8 in the Netherlands, the cost of the 2006 epidemic was estimated at 32.4 million euros. The
net costs of the BTV-8 epidemic of 2007 (BT2007) was valued at 164–175 million euros, depending on
the mortality and morbidity rates for cattle used. The losses accounted for 2%, 10% and 11% of the
gross value of the primary production within Dutch pasture-based livestock farming that equalled
1.6 billion euros. Control measures accounted for 91% of the net costs of the BTV-8 2006, while
diagnostic costs represented 7%. By contrast, for the BTV-8 2007, 92% of the net costs was in the
form of production losses and veterinary treatment fees, while only 6% were related to control
measures (Velthuis et al., 2010).
Velthuis et al. (2010) constructed a deterministic economic model to determine the cost of the
BTV-8 epidemic in the Netherlands during 2006 and 2007. Cattle, sheep and goat sectors were
incorporated and the model considered the impact of production, treatment of diseased animals,
diagnostic, and control measure costs. The criteria to assess the impact on production included
mortality, early culling, decreased milk production, weight loss, no gestations, post-poned gestations,
abortions, still births, decreased fertility of rams and lower birth weights (Table 5). All parameters were
based on expert opinion of private and government veterinarians, who were involved in the epidemic.
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Milk yield losses
Two studies attempted to use empirical data to quantify the reduction in milk yield due to BTV-8 on
immunologically na€ıve herds. A prospective study in the Netherlands monitored 15 seronegative herds
(1,074 cows) for seroconversion from July to December 2008 (Santman-Berends et al. 2011a). The
authors found that seroconverted cows produced 52 kg (95% CI 26–76) less milk (between 0.3% and
0.9% less) of the annual production. No effect on somatic cell count was detected. A study from
France quantiﬁed the mean impact on milk yield at the farm level and the duration of reduction before
and after the date disease was detected accounting for the risk of exposure at a district level
(Nusinovici et al., 2013). Over 3,000 Holstein herds were included in the study and the herds acted as
their own controls by comparing data from the same herd preoutbreak with what was subsequently
produced after BTV exposure. This study found that comparing the exposed and unexposed periods in
high-exposure areas, the mean cumulative loss was 3.4% of the annual 305-day production. This
period of reduction was between 2 months before to 4 months after the reported date of disease
detection in the herd.
Fertility losses
Several studies attempted to quantify the impact of BTV on fertility. Saegerman et al. (2011)
investigated an outbreak on a 355-ewe sheep ﬂock in Belgium of which around 60% had clinical
disease from July to September 2007. Data from four subsequent lambing periods were also presented
(November 2007, January 2008, March 2008 and May 2008). A higher rate of abortions of 15.7% was
detected in the lambing period in 2008; the rate was higher when compared to the rate of earlier
periods, which ranges between 0% and 5.7%. The authors also found that the fertility rate (number of
pregnant ewes/number of ewes used) had decreased down to 30% from the 59–76% recorded in
earlier periods (Saegerman et al., 2011).
Regarding cattle, Santman-Berends et al. (2010) monitored fertility on the 15 seronegative Dutch
herds. They found that infected cows were 5 times (95% CI 1.9–14.3) more likely to return to service
(RTS) within 56 days after ﬁrst insemination and were 1.7 times less likely (95% CI 1.4–2.0) to
become pregnant compared to non-infected cows.
On French dairy farms, Nusinovici et al. (2012) looked at the effect of BTV-8 on the 90 day RTS
rate after ﬁrst insemination, revealing an increased rate of between 8% and 21% comparing exposed
and non-exposed herds, depending on the time interval between the date of insemination and the
date of detection in the herd. In cantons of high exposure, this effect was estimated at between
13.5% and 26.8%. In a different study, the same authors also looked at the rate of late RTS between
90 and 200 days and short gestations. The authors reported an average effect of BTV-8 exposure with
a 6.7% increase in RTS and 1.9% increase in short gestations when exposed from the third month of
gestation inwards (Nusinovici et al., 2012). In Israel, BTV infection has not been associated with
fertility problems in cattle (Shimshony, 2004).
Table 5: The considered parameters for assessing the production impact in cattle, sheep, and goat
sectors used in the analysis of the BTV-8 economic impact in the Netherlands provided by
Velthuis et al. (2010). 2006: estimate from July 2006 to July 2007. 2007: estimate from
July 2007 to July 2008
Parameter
Cattle Sheep Goats
2006 2007 2006 2007 2006 2007
Early culling (%) 3 3 3 0 0 0
Weight loss (%) 7.0 7.0 8.1 8.1 – –
No gestation (%) 5.2 9.9 5.0 9.8 – –
Postponed gestation (%) 36.9 53.5 0.0 10.0 – –
Abortion (%) 2.0 6.2 1.9 3.2 – –
Reduced fertility rams (%)a – – 0.0 75.0 – –
Reduced birth weight (%) 2.6 6.7 – – – –
Stillbirths (%) 0.0 5.3 9 104 – – – –
Average daily milk production (kg/day) 26.9 26.9 2.0 2.0 2.48
Relative reduction milk production (%) 20 20 20 20 – 80
(a): Percentage of sheep farms that needed 1 extra ram.
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3.3.2.2. Article 7(b)(ii) The impact of the disease on human health
Humans are not susceptible to BTV and therefore there is no direct impact on public health.
3.3.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
The severity of clinical forms of BT for the ‘historical serotypes’ and the goat strains can be observed
from the impact table and deduced by the measure of morbidity, mortality and case fatality reported in
Table 1. In general for all ‘historical serotypes’, with the possible exception of BTV-16, the clinical form of
the disease are variable but can be severe, while for the serotypes BTV-25, -27, -30, it is asymptomatic.
After infection by insect bite, the virus replicates ﬁrst in the adjacent lymph node and then spreads
to infect vascular endothelium and macrophages/dendritic cells in many tissues/organs. Virus-induced
injury to endothelial cells in small blood vessels leads to vascular thrombosis and ischemic necrosis of
the tissues involved (DeMaula et al., 2002), which may induce lesions such as acute oral ulceration,
coronitis, muscle necrosis and vascular leakage leading to facial and pulmonary oedema as well as
pleural and pericardial effusion. These clinical conditions may lead to poor welfare in the animals to a
considerable degree, causing pain and malaise. Euthanasia is appropriate for animals with severe
muscle necrosis or severe coronitis, as these are unlikely to make a full recovery (Dercksen and Lewis,
2007). For these reasons, in several Member States legislation recognises and advocates the
euthanasia for the animals in these clinical conditions providing for farmer compensation.
3.3.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
The following wild animal species can be affected by the BTV serotypes from 1 to 24.
Species least concerned:
• Musk ox, Ovibos moschatus, Bovidae, Artiodactyla
• Alpine ibex, Capra ibex, Bovidae, Artiodactyla
• Siberian ibex, Capra sibirica, Bovidae, Artiodactyla
• Giraffe, Giraffa camelopardalis, Girafﬁdae, Artiodactyla
• Collared peccary, Pecari tajacu, Tayassuidae, Artiodactyla
• Eurasian lynx, Lynx lynx, Felidae, Carnivora
• Spotted hyena, Crocuta crocuta, Canidae, Carnivora
• Jackal, Canis mesomelas, Canidae, Carnivora
• Large spotted genet (Genetta tigrina), Viverridae, Carnivora
• White-tailed deer, Odocoileus virginianus, Cervidae, Artiodactyla
• Red deer, Cervus elaphus, Cervidae, Artiodactyla (Howerth et al., 2001; Fernandez-Pacheco
et al., 2008; Ruiz-Fons et al., 2008; Rodriquez-Sanchez et al., 2010)
• Wapiti elk, Cervus canadensis, Cervidae, Artiodactyla; (Howerth et al., 2001; Fernandez-Pacheco
et al., 2008; Ruiz-Fons et al., 2008; Rodriquez-Sanchez et al., 2010)
• Roe deer, Capreolus capreolus, Cervidae, Artiodactyla (Howerth et al., 2001; Fernandez-Pacheco
et al., 2008; Ruiz-Fons et al., 2008; Rodriquez-Sanchez et al., 2010)
• Axis deer, Axis axis, Cervidae, Artiodactyla; (Howerth et al., 2001; Fernandez-Pacheco et al.,
2008; Ruiz-Fons et al., 2008; Rodriquez-Sanchez et al., 2010)
• Fallow deer, Dama dama, Cervidae, Artiodactyla; (Howerth et al., 2001; Fernandez-Pacheco
et al., 2008; Ruiz-Fons et al., 2008; Rodriquez-Sanchez et al., 2010)
• Sika deer, Cervus nippon, Cervidae, Artiodactyla; (Howerth et al., 2001; Fernandez-Pacheco
et al., 2008; Ruiz-Fons et al., 2008; Rodriquez-Sanchez et al., 2010)
• Moose, Alces alces, Cervidae, Artiodactyla
• Reeve’s muntjac, Muntiacus reevesi, Cervidae, Artiodactyla
• Bighorn sheep, Ovis canadensis, Bovidae, Artiodactyla (Fernandez-Pacheco et al., 2008)
• Blue wildebeest, Connochaetes taurinus, Bovidae, Artiodactyla
• Black wildebeest, Connochaetes gnou, Bovidae, Artiodactyla
• Buffalo, Syncerus caffer, Bovidae, Artiodactyla (Tessaro and Clavijo, 2001; Niedbalski, 2015)
• Red hartebeest, Alcelaphus buselaphus, Bovidae, Artiodactyla
• Spanish ibex, Capra pyrenaica, Bovidae, Artiodactyla
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• Springbok, Antidorcas marsupialis, Bovidae, Artiodactyla
• Pronghorn, Antilocapra americana, Bovidae, Artiodactyla, (Tessaro and Clavijo, 2001;
Niedbalski, 2015)
Among the vulnerable species:
• Musk deer, Moschus moschiferus, Cervidae, Artiodactyla; (Howerth et al., 2001; Fernandez-
Pacheco et al., 2008; Ruiz-Fons et al., 2008; Rodriquez-Sanchez et al., 2010)
• Mouﬂon, Ovis orientalis, Bovidae, Artiodactyla (Fernandez-Pacheco et al., 2008)
• Arabian oryx, Arabian oryx, Bovidae, Artiodactyla
• Nubian ibex, Capra nubiana, Bovidae, Artiodactyla
• African elephant, Loxodonta africana, Elephantidae, Proboscidea
• Cheetah, Acinonyx jubatus, Felidae, Carnivora
• Lions, Panthera leo, Felidae, Carnivora
• European bison/wisents, Bison bonasus, Bovidae, Artiodactyla
Among the near threatened species:
• American bison, Bison bison, Bovidae, Artiodactyla (Tessaro and Clavijo, 2001; Niedbalski,
2015)
• White rhinoceros, Ceratotherium simum, Rhinocerotidae, Perissodactyla
• Blackbuck, Antilope cervicapra, Bovidae, Artiodactyla
Among the endangered species:
• African wild dogs, Lycaon pictus, Canidae, Carnivora
Among the critically endangered species:
• Wild bactrian camel, Camelus ferus, Camelidae, Artiodactyla
• Addax, Addax nasomaculatus, Bovidae, Artiodactyla
• Black rhinoceros, Diceros bicornis, Rhinocerotidae, Perissodactyla
Parameter 2 – Mortality in wild species
Data on mortality in wild animals have been described in Section 3.3.1.2 about case-fatality rate.
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
BTV, as a virus, can persist in the environment only inside the host and/or the vector. As mentioned
before, the virus could stay viable for many months and sometimes years in tissue and blood samples
stored refrigerated, or at 70°C. Apart from the viraemic host, vector midges play an important role in
maintaining the virus in the environment. They may play a role in the interseasonal maintenance of BTV
in temperate regions, so-called virus overwintering (Nevill, 1971; Wilson et al., 2008). The percentage of
Culicoides midges that become infected after taking a BTV-infected blood meal from an animal host can
vary with virus strain, Culicoides species/population and environmental factors, particularly temperature.
The infected midges can become infectious after an incubation period of approximately 10 days
(depending on ambient temperature), which is required for the virus to disseminate from the gut to the
salivary glands of the vector (Mullens et al., 1995; Mellor, 2000). Once infected with BTV, female midges
remain persistently infected for the remainder of their lives. Although the average life span of these is
usually ten to 20 days (Mellor, 2000), they can occasionally live for up to 3 months (Lysyk and Danyk,
2007). As explained above (Section 3.3.1.5) under favourable conditions, some biting midges can live
long enough to survive the period between two vector seasons (EFSA AHAW Panel, 2017a).
3.3.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Potential to generate crisis situation
BTV is among the pathogens that may generate high consequences for livestock industry and
trade, linked to direct and indirect losses, in particular at ﬁrst incursion in naive populations There are
example of crises generated I Sardinia (Italy) and Spain when BTV entered in naive small ruminant
populations.
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Potential use in bioterrorism
BTV is not included in the list of potential bioterrorist agents, neither for human nor for animal
diseases, neither in the list of the Encyclopaedia of Bioterrorism Defense of Australia Group or any
other list of potential bioagroterrorism agents.
3.3.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.3.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
The diagnostic methods for bluetongue and their purpose are indicated in the OIE Manual of
Diagnostic Tests and Vaccines for Terrestrial Animals (2017),6 as reported in Table 6.
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
See also Section 3.3.1.8.
Serological diagnosis of previous BTV infection of livestock is usually now done by c-ELISA that
detects antibodies to the BTV VP7 core protein (Afshar, 1994). When properly validated, the test is
highly sensitive and speciﬁc, and detects antibodies to most if not all serotypes and strains of BTV.
Antibodies detected by c-ELISA persist for long periods following BTV infection of animals, although
c-ELISA does not distinguish animals that were naturally infected with BTV from those that were
Table 6: Test methods available for the diagnosis of bluetongue and their purpose
Method
Purpose
Population
freedom
from
infection
Individual
animal
freedom
from
infection
prior to
movement
Contribute to
eradication
policies
Conﬁrmation
of clinical
cases
Prevalence
of infection –
surveillance
Immune
status in
individual
animals or
populations
post-
vaccination
Agent identiﬁcation(a)
Real-time
RT-PCR
– +++ – +++ ++ –
RT-PCR – +++ – +++ ++ –
Classical virus
isolation
– +++ – +++ – –
Detection of immune response
c-ELISA
(serogroup
speciﬁc)
++ +++ ++ – ++ ++
VN (serotype
speciﬁc)
++ +++ ++ – ++ ++
AGID + – + – + +
CFT + – + – + +
Key: +++ = recommended method; ++ = suitable method; + = may be used in some situations, but cost, reliability, or other
factors severely limits its application; – = not appropriate for this purpose.
Although not all of the tests listed as category +++ or ++ have undergone formal validation, their routine nature and the fact that
they have been used widely without dubious results, makes them acceptable.
RT-PCR = reverse-transcription polymerase chain reaction; c-ELISA = competitive enzyme-linked immunosorbent assay;
VN = virus neutralisation; AGID = agar gel immunodiffusion; CFT = complement ﬁxation test.
(a): A combination of agent identiﬁcation methods applied on the same clinical sample is recommended.
6 http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.01.03_BLUETONGUE.pdf
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immunised with current live-attenuated BTV vaccines (DIVA). It is to be stressed that the presence of
BTV-speciﬁc antibody by c-ELISA indicates only prior exposure to BTV and implies nothing about
disease causality or when that infection occurred. Serotype speciﬁc antibody is assessed using
virus-serum neutralisation assay in cell cultures, a procedure that takes several days and requires
specialised laboratory facilities to complete.
Identiﬁcation of BTV infection in animals is most readily accomplished using a group-speciﬁc
quantitative PCR (RT-qPCR) assay. Such assays now are routinely available in many diagnostic
laboratories, and at least one of these assays (based on detection of the S10 gene that encodes NS3
(Hofmann et al., 2008) has consistently identiﬁed all ﬁeld strains of BTV to date, regardless of serotype
and region of origin (genetic topotype). A distinct advantage of RT-qPCR over conventional PCR assays
is that the amount of viral nucleic acid in a sample can be quantitated, which can be useful in
ascribing disease causality; speciﬁcally, acutely affected animals generally have large amounts of BTV
nucleic acid in their blood and tissues, which is reﬂected by low Ct values on the RT-qPCR assay.
Critically, ruminants remain positive for BTV nucleic acid by PCR assay for up to 6 months or longer
following infection, meaning that the mere detection of viral nucleic acid by RT-qPCR is not proof of the
presence of infectious virus (Maclachlan et al., 1994; Bonneau et al., 2002; Maclachlan et al., 2009; OIE,
2013a). Unlike conventional RT-PCR assays, the real-time RT-PCR assays can be used in a ‘closed- tube’
format, reducing the risk of contaminating the working laboratory environment with ampliﬁed DNA, and
therefore reducing the risks of false positive results. Serotype-speciﬁc PCR assays can be used to type the
virus present in samples that are positive by group-speciﬁc assay (Maan et al., 2012a,b; Mayo et al.,
2012). The availability of these assays has largely obviated the need for virus isolation as part of
diagnostic testing and ‘typing’, which is complex, laborious, expensive and typically takes several weeks
to perform. Hence, virus isolation requires specialised laboratory facilities. Furthermore, some virus
strains require initial propagation in embryonated chicken eggs before they will grow in cell culture
systems. However, virus isolation does demonstrate conclusively that the viral RNA detected by RT-PCR is
present in infectious virus particles, not just as RNA or DNA copies of the viral genes.
Quantitative assessment of the diagnostic sensitivity and speciﬁcity of tests used in the EU
monitoring and surveillance programmes is important to allow the establishment of the predictive
values of positive and negative results for a given prevalence. Vandenbussche et al. (2008) reported a
diagnostic sensitivity and speciﬁcity for the real time RT-PCR of 99.5% (95% CI: 99.0–100) and 98.5%
(97.1–100), respectively. Based on these ﬁgures, this test is good for using during monitoring and
surveillance in phases 2–4, however, when testing large numbers of negative animals (phase 1 or 5)
some false positive test results may be observed. Speciﬁcity can be increased if positive results are
subsequently tested by a serotype speciﬁc PCR. Moreover, the epidemiological situation can be taken
into account in case of unforeseen positive results. Consequently, PCR is a good test for the purpose of
monitoring and surveillance. However, standardisation of this assay between different countries and
laboratories is required.
The outcomes of the most up-to-date systematic review on the sensitivity and speciﬁcity of c-ELISA
are provided in Table 7.
Regarding the performances of milk ELISAs, they depend on the herd prevalence. Mars et al.
(2010) reported a herd sensitivity of 88% (95% CI 80–94) at a within-herd prevalence of 1%,
accompanied by a speciﬁcity of 100% (95% CI 96–100), and a herd sensitivity of 100% (95% CI
96–100) at a within-herd prevalence of 10%, accompanied by a speciﬁcity of 93% (86–98).
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
• Midges
• Live animals: blood in EDTA
Table 7: Summary outcomes of systematic review on the sensitivity and speciﬁcity of diagnostic
tools used to detect BTV infections (papers published up to January 2016)
Diagnostic tool type Species Sensitivity range (%) Speciﬁcity range (%)
Competitive ELISA (c-ELISA) Cattle 89.2 (83.0–100) 98.4 (95.8–99.5)
Sheep 83.8 (12.8–91.1) 95.5 (69.5–99.8)
Goats 92.8 94.8
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• Freshly dead animals: spleen, lymph nodes, red bone marrow, heart blood
• Aborted and congenitally infected newborn animals: spleen, brain, lymph nodes
• All samples have to be preserved at 4°C, and not frozen (20°C)
• Paired sample sera
See also Section 3.3.1.8.
3.3.4.2. Article 7(d)(ii) Vaccination
Availability
Parameter 1 – Types of vaccines available on the market (live, inactivated, DIVA, etc.)
The ﬁrst generation of commercial bluetongue vaccines was live attenuated vaccines (LAVs). For the
largest part of the 20th century, use of these vaccines was restricted to southern Africa and North
America, and intended to limit clinical disease. South African vaccines contain in total 15 serotypes
divided in three pentavalent vaccines subsequently injected with intervals of 3–4 weeks, resulting in
broad cross-protection against the multiplicity of BTV serotypes endemic to the region (Dungu et al.,
2004).
In North America, similar LAVs for prevailing serotypes were developed and used in sheep and captive
cervids since the 1950s. Autogenous, inactivated vaccines are also available. They are custom-made
vaccines that contain herd speciﬁc (homologous) antigens. They usually contain combinations of BTV and
EHDV antigens. Little published data are available for the evaluation of these products (McVey and
Maclachlan, 2015).
In the late 1990s, the BTV incursion in southern Europe led brieﬂy to the use of South African LAV
in Italy, Corsica and Spain (Zientara and Sanchez-Vizcaino, 2013, Perez de Diego et al., 2011). Safety
considerations led to the development of safer, inactivated vaccines, against the serotypes relevant to
the European outbreak situation. The ﬁrst commercial BT vaccine of the second generation (i.e.
inactivated vaccines) was introduced by Merial in Italy in 2003, under Temporary Authorisation of Use
(Savini et al., 2008). Several European manufacturers introduced other inactivated vaccines in Europe
under the same regulatory framework: temporary authorisations of use, conditional licences or
registrations under exceptional circumstances. These temporary authorisations were later converted
into full marketing authorisations (Saegerman et al., 2007; Savini et al., 2008)
Registration in the EU follows the strict regulatory guidelines set by the European Pharmacopeia
and the EMA Committee for Medicinal Products for Veterinary Use (CVMP). Production must follow
European Good Manufacturing Practices (EU-GMP).
LAVs were used in India until 2015 followed by the introduction of inactivated vaccines (Ranjan
et al., 2015). An inactivated pentavalent vaccine is in current use in India.
In China, inactivated vaccines have been produced and used in several provinces in response to
outbreaks (Zhang et al., 2004), but little information on these products is available and they do not
seem to be part of regular vaccination programs.
Vaccines of the third generation (recombinant and engineered vaccines) have proven to be safe
and effective at the experimental scale, and have the potential to address some of the weaknesses of
inactivated vaccines, like DIVA capability, rapid onset of immunity and cross-serotype protection.
However, development and registration of a new vaccine represents a major R&D investment, and
would be justiﬁed ﬁnancially for a manufacturer only by a signiﬁcant advantage over existing
inactivated vaccines. As of 2017, none has been registered and made available commercially. Vaccines
by country of registration are listed in Table 8.
Table 8: Vaccines by country of registration
Company
Product
Name
Serotype
Vaccine
type*
Adjuvant
License
countries
Indications
Vaccines licensed for use in the EU
Bioveta BioBos BTV8 8 I Aluminium
hydroxide,
Saponin
Czech
Republic
Cattle, Sheep
CZ Veterinaria BLUEVAC BTV8 8 I Aluminium
hydroxide,
Saponin
EU Cattle, Sheep
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Company
Product
Name
Serotype
Vaccine
type*
Adjuvant
License
countries
Indications
CZ Veterinaria BLUEVAC-1 1 I Aluminium
hydroxide,
Saponin
Spain,
France
Cattle, Sheep
CZ Veterinaria BLUEVAC-4 4 I Aluminium
hydroxide,
Saponin
Spain Cattle, Sheep
Merial BTVPUR AlSap 1, 8, 2, 4 +
any combination
of 2 of these
strains**
I Aluminium
hydroxide,
Saponin
EU Cattle, Sheep
Merial BTVPUR AlSap 9 9 I Aluminium
hydroxide,
Saponin
Italy Cattle, Sheep
MSD Animal Health Bovilis BTV-8 8 I Aluminium
hydroxide,
Saponin
EU Cattle, Sheep
Syva Syvazul-1 1 I Aluminium
hydroxide,
Saponin
EU Cattle, Sheep
Syva Syvazul-1+8 1, 8 I Aluminium
hydroxide,
Saponin
Spain Cattle, Sheep
Syva Syvazul-4 4 I Aluminium
hydroxide,
Saponin
Spain Sheep
Syva Syvazul-8 8 I Aluminium
hydroxide,
Saponin
Spain Cattle, Sheep
Zoetis ZULVAC 1 +
8 Ovis
1+8 I Aluminium
hydroxide,
Saponin
EU Sheep
Zoetis ZULVAC 8 Ovis 8 I Aluminium
hydroxide,
Saponin
EU Sheep
Zoetis ZULVAC 8 Ovis 8 I Aluminium
hydroxide,
Saponin
EU Cattle
Zoetis ZULVAC 1 Ovis 1 I Aluminium
hydroxide,
Saponin
EU Sheep
Zoetis ZULVAC 1 Bovis 1 I Aluminium
hydroxide,
Saponin
EU Cattle
Zoetis ZULVAC 1 +
8 Bovis
1+8 I Aluminium
hydroxide,
Saponin
EU Cattle
Zoetis Zulvac 4 Ovis 4 I Aluminium
hydroxide,
Saponin
Spain Sheep
Vaccines licensed for use in India
Biovet Private
Limited
BioBT-Oil 1+2+10+16+ 23 I Oil India Sheep and
Goats
Biovet Private
Limited
BioBT-Gel 1+2+10+16+ 23 I Aluminium
hydroxide,
Saponin
India Sheep and
Goats
AHL assessment on bluetongue
www.efsa.europa.eu/efsajournal 43 EFSA Journal 2017;15(8):4957
Effectiveness
Parameter 3 – Field protection as reduced morbidity (as reduced susceptibility to infection and/or to
disease)
Data about protection conferred by BT vaccine are shown in Table 9.
Company
Product
Name
Serotype
Vaccine
type*
Adjuvant
License
countries
Indications
Indian
Imunologicals
Raksha Blu 1+2+10+16+ 23 I Aluminium
hydroxide,
Saponin
India Sheep and
Goats
Vaccines licensed for use in China PR
Yunnan Tropical
and Subtropical
Animal Virus
Disease Laboratory
Bluetongue
vaccine
1+16 LAV
I
? China PR Sheep and
Goats
Vaccines licensed for use in Morocco
Biopharma BTVAC 1+4 LAV Morocco Sheep and
Goats
MCI Sante Animale OVIVAX BT1+4 1+4 LAV Morocco Sheep and
Goats
Vaccines licensed for use in Russia
National Research
Institute for
Veterinary Virology
and Microbiology of
Russia
Bluetongue
Vaccine
1,6,8,4,9,16 I Aluminium
hydroxide,
Saponin
Russia Sheep and
Goats
Vaccines licensed for use in South Africa
Onderstepoort
Biological Products
Bluetongue
Vaccine
For Sheep
A: 1+4+6+12+14
B:3+8+9+10+11
C:2+5+7+13+19 *
LAV South Africa Sheep
Vaccines licensed for use in Turkey
Etlik Veterinary
Control Central
Research Institute
Blue-T4 ETVAC
Mavi Dil Asisi
4 LAV Turkey Sheep
Vaccines licensed for use in the USA
Colorado Serum
Company
Bluetongue
Vaccine
10 LAV USA Sheep and
Goats
Newport
Laboratories
Custom made
EHD+BTV
Vaccine
Autogenous EHD
+ BTV, serotypes
on demand
(EHD1+2 +6
BTV17+3)
I, CM Oil USA Cervids only
Poultry Health
Laboratories (PHL)
BlueVac 10, 11, 17 LAV California Sheep
*: I = inactivated; LAV = Modiﬁed Live Virus; CM = Custom-Made (autogenous).
**: BTVPUR was registered under the multistrain guideline that allows combinations of strains suited to the epidemiology.
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Parameter 4 – Duration of protection
LAVs confer lifelong protection as with natural infection. For inactivated vaccines, producers
recommend annual booster, thus immunity is supposed not to be longer than 12 months.
For inactivated vaccine of BTV-2 and 4, two doses fully protect sheep for up to 12 months, while in
cattle although a single dose of BTV-4 inactivated vaccine prevented viraemia in vaccinated animals
challenged 2 weeks after vaccination, a single vaccination did not fully prevent viraemia in animals
challenged 7 months after vaccination (Savini et al., 2008). For the inactivated BTV serotype 8, the
duration of immunity is not yet fully established in cattle or sheep, although interim results of ongoing
studies demonstrate that the duration is at least 6 months after the primary vaccination course in sheep.7
Feasibility
Parameter 5 – Way of administration
Live-attenuated BT vaccines are administered subcutaneously whereas inactivated BT vaccines may
be administered by subcutaneous or intradermal injection. Currently used live-attenuated or inactivated
BTV vaccines have reported protective immunity upon challenge between 7 and 12 months and yearly
revaccination is often conservatively adopted in the ﬁeld (Savini et al., 2004b; Hamers et al., 2009a,b;
Oura et al., 2009; Waeckerlin et al., 2010). Booster vaccination increased the antibody responses
Table 9: Detailed references and values from a systematic review on the efﬁcacy of BTV vaccines
approved for commercialisation in the European Union (papers published up to January
2016)
Vaccine
commercial name
(BTV serotype)
Doses Species Efﬁcacy
Prevention of
clinical signs
Breard et al.
(2015)
BTVPUR ALSAP 8 1 Sheep Full protection against BTV
serotype 8 in challenge 21 days
after vaccination (no viraemia,
demonstrated immunogenicity)
Clinical scores summed
over 2 weeks after
challenge were 7 times
smaller than controls
Breard et al.
(2015)
BTVPUR ALSAP
2,4
2 Sheep Poor protection against BTV
serotype 8 (viraemia and clinical
signs detected after challenge,
no neutralising antibodies on
the day of challenge)
Clinical scores summed
over 2 weeks after
challenge were not
signiﬁcantly lower than
controls
Gubbins
et al. (2012)
Bovilis BTV8 2 Cattle Efﬁcacy calculated based on number of infections
prevented (proportional reduction) = 75% (CI: 60–85)
Gubbins
et al. (2012)
Bovilis BTV8 1 Sheep Efﬁcacy calculated based on number of infections
prevented (proportional reduction) = 98% (CI: 89–100)
Moulin et al.
(2012)
Bovilis BTV8 1 Sheep
(young
animals)
High protection against BTV
serotype 8 in challenge 21 days
after vaccination (1/16 animals
showing viraemia,
demonstrated immunogenicity)
Clinical scores summed
over 2 weeks after
challenge were 8–10
times smaller than
controls
Moulin et al.
(2012)
Bovilis BTV8 1 Sheep
(adults)
High protection against BTV
serotype 8 in challenge 21 days
after vaccination (2/12 animals
showing viraemia,
demonstrated immunogenicity)
Clinical scores summed
over 2 weeks after
challenge were 4–7
times smaller than
controls
Breard et al.
(2011)
Bovilis BTV8 2 Goats Full protection against BTV
serotype 8 in challenge 21 days
after vaccination (no viraemia,
demonstrated immunogenicity)
Not reported
Breard et al.
(2011)
BTVPUR ALSAP 8 2 Goats Full protection against BTV
serotype 8 in challenge 21 days
after vaccination (no viraemia,
demonstrated immunogenicity)
Not reported
7 http://www.merial.co.uk/Livestock/Pages/bluetongue.aspx
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compared to single vaccinations, and, especially in cattle, repeated vaccination and a high dose is
considered necessary for long-lasting protection (Hund et al., 2012). Surprisingly, however, anti-BTV
antibodies including neutralising antibodies have been reported for up to 4 years in ruminants
following the BTV-8 vaccination campaign using different inactivated preparations (Eschbaumer et al.,
2012; Oura et al., 2012; Batten et al., 2013b). Although protection was not conﬁrmed in challenge
experiments, vaccination with inactivated vaccines may potentially protect ruminants for longer periods
than initially assumed.
3.3.4.3. Article 7(d)(iii) Medical treatments
No speciﬁc treatment is available, other than supportive care. Symptomatic treatment and care
includes non-steroidal anti-inﬂammatory drugs (NSAID) to reduce pain, ﬂuid therapy to treat or
prevent dehydration, provision of shade against the sun, protection against extremes of temperature,
use of mild disinfectants to irrigate affected areas, general nursing care, the provision of a trough of
cool water in which affected animals can cool their muzzle, provision of soft green foods during the
period when the mouth lesions are painful, and long-acting antibiotics against secondary bacterial
diseases. For animals with severe coronitis or severe muscle necrosis, euthanasia is appropriate
(Dercksen and Lewis, 2007; Kaandorp-Huber, 2008).
Cattle are more likely to recover more quickly than are sheep. Affected sheep should be housed to
protect them from direct sunlight and from extreme temperatures and offered soft green foods while
the mouth lesions are painful (Veterinary Research Laboratory Onderstepoort, 1963). If necessary,
ﬂuids and electrolytes could be given. It may be necessary to control secondary infections. Mild
disinfectants may be used to irrigate affected areas; this may provide some relief for affected animals.
(Radostits et al., 2007).
3.3.4.4. Article 7(d)(iv) Biosecurity measures
Since bluetongue (serotypes BTV-1–24) is considered to be non-contagious by direct contact,
isolation of infected animals is not necessary or appropriate for disease control. Other measures could
be adopted in order to reduce the contact between hosts and vectors.
Recently, the effectiveness of vector-control measures has been reviewed in an EFSA opinion (EFSA
AHAW Panel, 2017a), and compared to the effectiveness of vector-proof establishments. It was
concluded that there is no conclusive evidence that the use of insecticides or repellents when applied
singularly reduce the transmission of BTV in the ﬁeld. In speciﬁc scenarios, however, they have been
shown to either kill Culicoides or reduce host/vector contact and hence are used as a risk mitigation
measure where vaccines are unavailable.
Housing of livestock during the times when the vector midges are most active, i.e. dusk to dawn,
should signiﬁcantly reduce rates of biting by exophilic vectors (Osburn, 2000; Mellor and Wittmann,
2002). The effectiveness of stabling or protective housing is likely to vary considerably depending on the
Culicoides species involved as well as how “midge-proof” the housing is (Carpenter et al., 2008a,b).
Screens applied on openings (windows, doors) using ﬁne mesh capable of excluding midges, or
coarser mesh impregnated with a suitable insecticide such as a synthetic pyrethroid should further
reduce the attack rate (EFSA AHAW Panel, 2017a).
Treatment of animals with pour-on insecticides causes mortality in a proportion of feeding
Culicoides; thus, preventing further onward transmission from a host that is infected and viraemic,
thereby helping to stop further spread of the outbreak. However, the effect is transient and
necessitates frequent application. Furthermore, high level of efﬁcacy (up to 86%) of pour-on
insecticides is difﬁcult to achieve, particularly under ﬁeld conditions, and little information is available
about the effect of reduction on the numbers of engorged Culicoides females in relation to BTV
transmission (EFSA AHAW Panel, 2017a). Repellents that act prior to feeding may be more likely to
prevent Culicoides feeding and could therefore prevent the initial infection of a susceptible and na€ıve
animal. Nevertheless treatment of animals with repellent products (e.g. diethyl toluamide (DEET)) has
been less investigated, largely due to the logistics of reapplication every few hours. This is unlikely to
be feasible except for very high value stock (EFSA AHAW Panel, 2017a).
3.3.4.5. Article 7(d)(v) Restrictions on the movement of animals and products, as control
measure
The movement control of animals and biological products can limit the spread of BTV infection
between different regions and countries. However, in the restricted areas or where the virus circulates
the movement control alone cannot prevent the spread of infection by vectors.
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The strict control of animal movements is one of the key factors for the control of BT spread,
especially when coupled with the vaccination of susceptible animals in infected areas and the
implementation of surveillance activities able to monitor the BTV circulation and to assess the risk of
disease spread (Caporale and Giovannini, 2010). From 2000 to 2006 the above mentioned approach
was applied in southern Europe countries like Italy, Spain and Portugal, allowing at limiting the spread
of the infection northward, although the complete eradication of the infection was achieved only in few
limited cases (Caporale and Giovannini, 2010).
The legal basis for the movement restrictions is laid down in Council Directive 2000/75/EC and
Commission Regulation (EC) No 1266/2007. Further information is provided on the dedicated webpage
of DG SANTE.8
3.3.4.6. Article 7(d)(vi) Killing of animals
As a vector-borne disease stamping out is unlikely to have much effect and therefore there is no
justiﬁcation for it in case of bluetongue. This is partly because the virus is considered likely to be
already present in the vector population, and the infected midges would be unaffected by removal of
infected host animals. In a few cases, however, some animals may need to be euthanised for welfare
reasons.
3.3.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Among the routes of transmission, it has been described that BTV can be transmitted via oral route
for example to carnivores (Section 3.3.1.6). Even though this may be a rare event, the correct disposal
of infected carcases can prevent this occurrence.
3.3.5. Article 7(e) The impact of disease prevention and control measures
3.3.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Detailed studies on evaluation of costs are available only for BTV-8 epidemics in 2006–2009. These
may include:
• cost of control (e.g. treatment/vaccine, biosecurity)
• cost of eradication (culling, compensation)
• cost of surveillance and monitoring
• trade loss (bans, embargoes, sanctions) by animal product
• importance of the disease for the affected sector (% loss or euros lost compared to business
amount of the sector)
Bluetongue is often said to be a disease with potential economic consequence qualifying it as a
notiﬁable disease by the OIE. A global estimate of the impact of BT was US$3 billion (Bath, 1989).
Southern regions of the US are endemic for some types of foot and mouth disease (FMD), which
restricts trade of livestock and related products. This indirect cost has been estimated at US
$125 million annually (Tabachnick, 1996). With regard to the BTV-8 outbreaks, Wilson and Mellor
(2009) stated that the ‘BTV-8 epidemic in northern Europe has probably caused greater economic
damage than any previous single-serotype Bluetongue outbreak’.
In epidemic situations, e.g. BTV-8 epidemic in northern Europe, in 2007, the overall estimates on
the ﬁnancial impact in France and the Netherlands were US$1.4 billion and US$85 million, respectively.
The costs are largely ascribed to the trade restrictions that were present during the outbreak period. A
study commissioned by the Scottish Government led to the development of a model to estimate the
economic impact of different incursion scenarios and the beneﬁt-cost ratio of various control scenarios.
The assessment of the impact on production was based on expert opinion. The direct costs, which
incorporated reduced milk production, weight loss, mortality, veterinary treatments, and animal testing,
were estimated at £30 million per year.
In the economic model developed by Velthuis et al. (2010) to determine the cost of the BTV-8
epidemic in the Netherlands during 2006 and 2007, the overall cost was estimated to be €32.4 and
€164–175 million in 2006 and 2007, respectively. The authors estimated that control measures made
up 91% of the cost in 2006. In 2007, due to the relaxation of control measures and the greater
number of farms affected production losses and veterinary treatment fees made up 92% of the total
8 https://ec.europa.eu/food/animals/animal/diseases/control-measures/bluetongue_en
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costs. In response to uncertainty over the availability of vaccines, the same model was used to assess
the relative beneﬁts of different vaccine strategies for controlling a BTV-8 epidemic in 2008 (Velthuis
et al., 2011). While, the production losses were the same as those estimated in 2007 with the original
model, although the mortality, morbidity, and number of infected farms varied in the two scenarios.
The overall ﬁnancial impact (including production losses, diagnostics, treatment, and control measures)
ranged from €40.9 to €41.3 million, with most losses being estimated to occur on sheep breeding
farms, dairy export ﬁrms, and dairy ﬁrms (€12.6, €12.6 and €11.3 million, respectively). The highest
impact was ascribed to production losses at 52.8% and 55.2% of the total net costs for the two
scenarios under consideration.
As part of an evaluation of the surveillance and control program in Switzerland, H€asler et al. (2012)
used a stochastic economic model to compare hypothesised baseline strategies with the interventions
actually employed as part of retrospective (2008–2009) and prospective (2010–2012) analyses. In the
retrospective baseline scenario, the mean estimated disease costs in 2008 and 2009 were €12.2 million
and €3.6 million, respectively. In the 2011 and 2012 prospective baseline scenarios, the mean costs
ranged between €2.6 million and €6.6 million per year, depending on the scenario being considered.
As with the other studies, production losses were based mainly on expert opinion. The authors
remarked that ‘one major limitation of the present model was the lack of reliable data to estimate total
disease costs’.
Movement restriction policy (MRP) was also the major cause of economic losses during BTV-8
2006–2007 BTV-8 outbreaks. In 2007, BTV outbreaks in France were estimated to cost $1.4 billion
(Tabachnick et al., 2008). The French cattle industry accounts for 20% and 33% of the European dairy
and suckling cows, respectively. Most of the 4 million suckling calves are born in winter and spring,
and 1.4 million animals (mainly males) are sold yearly as beef weaned calves (BWC) around
6–9 month sold (more than 1,000 million euros of value). Most (66%) are sent abroad (Loirette-Baldit,
2008), with others sold to fattening units in France. Exports are deﬁned here as BWC sold and sent
out of France, either within or outside the EU. For these calving systems, MRP has a huge impact:
timing for selling is crucial to fulﬁl contracts with fattening barns abroad, and farms have some limited
stocking capacity, in particular during winter. In the French 2006, BTV-8 outbreak, farmers experienced
a 21% decrease in animals sold due to the MRP (Tago et al., 2014).
Costs are also due to the surveillance programmes put in place for early detection of possible BTV
introduction. The total net cost of the BTV-8 surveillance and vaccination programmes in Austria
arising from the outbreak amounted to 22.8 million euro (0.86% of the national agricultural Gross
Value Added), of which 32% was allocated to surveillance and 68% to the vaccination programme
(Pinior et al., 2015).
Gunn et al. (2008) developed an economic model to identify, measure and value disease costs for
various scenarios of BT introduction and spread in Scotland and to evaluate disease mitigation
strategies. Baseline costs of surveillance and prevention were estimated to be £141 million over a
5-year time horizon and it was found that the beneﬁts of avoiding disease incursion exceeded the
costs of surveillance and prevention. Economic evaluation indicated control option 4 was likely to yield
the greatest economic beneﬁt. Direct costs (approx. £30 million per annum) were much smaller than
indirect costs (loss of markets, price effects etc.). Although indirect costs are difﬁcult to estimate, our
results suggested that they may exceed £70 million per annum, reinforcing the importance of
investment in baseline costs that reduces risk and limits incursions.
In endemic situation, especially in the southern hemisphere, it is clinically difﬁcult, particularly in
cattle, to detect and report new cases in passive surveillance systems, because the occurrence of BT
may not be considered clinically signiﬁcant to farmers. However, in this particular situation, one of the
direct measurable economic impacts of BT on a local scale is the cost and the management of animal
vaccination for control and prevention of the disease. Vaccination measures associated with preventive
local economic factors of BT generally have a high economic impact and are complicated in some
circumstances by the multiple serotypes associated with these diseases. Multiple inoculations per
season are required. In southern African countries, the multivalent Onderstepoort Biological Products
vaccine is widely used (Dungu et al., 2004). This vaccine is given in three doses consisting of 15
serotypes of attenuated BTV ﬁeld strains. The economic impact based on vaccine sales in South Africa
amounts to approximately US$2 million per year for a vaccination coverage of approximately 25% of
the population (Grewar, 2016). This creates challenges in maintaining vaccine coverage and
compliance, where applicable. In the majority of southern African regions, endemic BT may not be
considered clinically signiﬁcant to farmers, because they are more familiar with the disease. This might
lead to an underestimation of the costs of the disease, especially when considering that in dairy
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farming BT can signiﬁcantly inﬂuence production (Barnard et al., 1998). The situation in the southern
European countries where BT is endemic is slightly different. Vaccination campaigns are based on the
use of inactivated vaccines and the costs are even higher. A dose of inactivated vaccine is around
0.8–1 euro for monovalent vaccine dose and 1.2 euro for a bivalent vaccine dose. In addition most of
inactivated vaccines require a booster dose 3–4 weeks after the ﬁrst injection and then yearly booster
dose.
3.3.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
Not applicable.
3.3.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
Not applicable.
Parameter 2 – Wildlife depopulation as control measure
Not applicable.
3.3.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
In theory, vector control of Culicoides both larvae and adults appears as a potentially useful method
to reduce BTV transmission in scenarios when vaccine for a particular serotype is not available, there
are several serotypes circulating, the serotype/strain is low pathogenic and/or movement restrictions
and protection of animals from vector bites are the only way to reduce transmission. Vector control
could be also appropriate under emergency outbreak situations or where vaccines are not economically
affordable (Harrup et al., 2015; Purse et al., 2015). In practice, the control of Culicoides and its impact
on virus transmission at farm level is still poorly implemented and in most of the cases impractical from
an environmental and technical point of view. The general classiﬁcation of control methods are
considered in (i) mechanical, (ii) chemical, (iii) biological, (iv) genetic and (v) biotechnological, and are
reviewed in detail in a recent EFSA output (EFSA AHAW Panel, 2017a).
Concerning a possible environmental impact of insecticides for BTV control, in the same EFSA
opinion, it has been concluded that there is no evidence on treatment of the environment with
insecticides to kill either adult or larval Culicoides and it is unlikely to be effective due to the ubiquitous
nature of Culicoides larval development sites in Europe. The high costs of other chemical treatments
for BT vector control like pour-on insecticides or repellent products applied on animals do not allow
large scale use of these products, thus unlikely to lead to an environmental damage.
Biodiversity
Parameter 2 – Mortality in wild species
See Section 3.3.2.4.
3.4. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
(Table 10) according to the strata of BT strains grouped as in Section 3.2:
• BTV strains belonging to serotypes BTV-1, -2, -4, -8, -9, that have circulated or are still
circulating in some parts of Europe (deﬁned from now on as BTV-1–24).
• Some strains of serotypes BTV-16 still circulating in some parts of Europe (deﬁned from now
on as BTV-16).
• Small ruminant-adapted strains, BTV strains belonging to serotypes BTV-25, -27, -30 and
related isolates (deﬁned from now on as BTV-25–30).
The expert judgement was based on Individual and Collective Behavioural Aggregation (ICBA)
approach described in detail in the opinion on the methodology (EFSA AHAW Panel, 2017b). Experts
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have been provided with information of the disease fact-sheet mapped into Article 5 criteria (see
supporting information, Annex B), based on that the experts indicate their Y/N or ‘na’ judgement on
each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 10. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017b). For details on the
interpretation of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel,
2017b).
3.4.1. Outcome of the assessment on bluetongue according to criteria of Article
5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017b), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 10, BTV-1–24
complies with all criteria of the ﬁrst set and with three criteria of the second set, therefore they are
considered eligible to be listed as laid down in Article 5 of the AHL. BTV-25–30 and BTV-16 do not
comply with criterion A(iii), therefore they are not considered eligible to be listed as laid down in
Article 5 of the AHL.
3.5. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about bluetongue (Tables 11, 12, 13, 14 and 15). The expert
judgement was based on Individual and Collective Behavioural Aggregation (ICBA) approach described
in detail in the opinion on the methodology. Experts have been provided with information of the
disease fact-sheet mapped into Article 9 criteria (see supporting information, Annex B), based on that
Table 10: Outcome of the expert judgement on the Article 5 criteria for bluetongue
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of
paragraph 1 of Article 5 if it has been assessed in accordance with Article 7 and meets
all of the following criteria
Final outcome
BTV-
1–24
BTV-
25–30
BTV-
16
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs
thereof exist in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public
health due to its zoonotic character
Y N
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are
effective and proportionate to the risks posed by the disease in the Union
Y na* Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on
animal health, or poses or could pose a signiﬁcant risk to public health due to
its zoonotic character
Y N
B(ii) The disease agent has developed resistance to treatments and poses a
signiﬁcant danger to public and/or animal health in the Union
na
B(iii) The disease causes or could cause a signiﬁcant negative economic impact
affecting agriculture or aquaculture production in the Union
Y N
B(iv) The disease has the potential to generate a crisis or the disease agent could be
used for the purpose of bioterrorism
Y N
B(v) The disease has or could have a signiﬁcant negative impact on the
environment, including biodiversity, of the Union
N
Colour code: green = consensus (Yes/No); red = not applicable (na), i.e. insufﬁcient evidence or not relevant to judge
*: These strains have never been controlled; control measures might not be justiﬁed, since their impact is minimal. Therefore,
although control measures may be proportionate, it is not possible to assess the effectiveness of risk-mitigating measures.
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the experts indicate their Y/N or ‘na’ judgement on each criterion of Article 9, and the reasoning
supporting their judgement.
The minimum number of judges in the judgement was 9. The expert judgement was conducted as
described in the methodological opinion (EFSA AHAW Panel, 2017b). For details on the interpretation
of the questions see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017b).
Table 11: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for bluetongue
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final outcome
BTV-
1–24
BTV-
25–30
BTV-
16
1 The disease is not present in the territory of the Union OR present only in
exceptional cases (irregular introductions) OR present only in a very limited
part of the territory of the Union
N NC N
2.1 The disease is highly transmissible NC
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y na Y
2.3 The disease affects multiple species of kept and wild animals OR single
species of kept animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates Y* N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public
health, including epidemic or pandemic potential OR possible signiﬁcant
threats to food safety
N
4 (CI) The disease has a signiﬁcant impact on the economy of the Union, causing
substantial costs, mainly related to its direct impact on the health and
productivity of animals
Y N
4 (PI) The disease has a signiﬁcant impact on the economy of the Union, causing
substantial costs, mainly related to its direct impact on the health and
productivity of animals
Y N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact
on labour markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact
on labour markets
Y N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering
of large numbers of animals
Y N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering
of large numbers of animals
Y N
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct
impact of the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct
impact of the disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or
the protection of endangered species or breeds, including the possible
disappearance or long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or
the protection of endangered species or breeds, including the possible
disappearance or long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC); red = not applicable (na), i.e. insufﬁcient evidence or
not relevant to judge.
*: According to the interpretation of this criterion as described in the methodology opinion, which considers the potential of the
disease to have high morbidity and/or high mortality, the potential morbidity and mortality levels have been assessed
considering possible values in all susceptible animals, despite the low levels of morbidity and mortality usually observed in
cattle.
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Table 12: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for bluetongue
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final outcome
BTV-1–
24
BTV-25–
30
BTV-
16
1 The disease is present in the whole OR part of the Union territory
with an endemic character AND (at the same time) several Member
States or zones of the Union are free of the disease
Y NC Y
2.1 The disease is moderately to highly transmissible Y N
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y na Y
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality Y* N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on
public health, including epidemic potential OR possible signiﬁcant threats
to food safety
N
4 (CI) The disease has a signiﬁcant impact on the economy of the Union,
causing substantial costs, mainly related to its direct impact on the health
and productivity of animals
Y N
4 (PI) The disease has a signiﬁcant impact on the economy of the Union,
causing substantial costs, mainly related to its direct impact on the health
and productivity of animals
Y N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an
impact on labour markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an
impact on labour markets
Y N
5(b)
(CI)
The disease has a signiﬁcant impact on animal welfare, by causing
suffering of large numbers of animals
Y N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing
suffering of large numbers of animals
Y N
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the
direct impact of the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the
direct impact of the disease OR due to the measures taken to control it
N
5(d)
(CI)
The disease has a signiﬁcant impact on a long-term effect on biodiversity
or the protection of endangered species or breeds, including the possible
disappearance or long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity
or the protection of endangered species or breeds, including the possible
disappearance or long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC); red = not applicable (na), i.e. insufﬁcient evidence or
not relevant to judge.
*: According to the interpretation of this criterion as described in the methodology opinion, which considers the potential of the
disease to have high morbidity and/or high mortality even in absence of control measures, the potential morbidity and
mortality levels have been assessed considering possible values in all susceptible animals, despite the low levels of morbidity
and mortality usually observed in cattle.
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Table 13: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for bluetongue
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final outcome
BTV-1–
24
BTV-25–
30
BTV-
16
1 The disease is present in the whole OR part of the Union territory with
an endemic character
Y N Y
2.1 The disease is moderately to highly transmissible Y N
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible
or no mortality AND often the most observed effect of the disease is
production loss
N N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on
public health, or possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of parts of the
Union, mainly related to its direct impact on certain types of animal
production systems
N
4(PI) The disease has a signiﬁcant impact on the economy of parts of the
Union, mainly related to its direct impact on certain types of animal
production systems
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an
impact on labour markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an
impact on labour markets
Y N
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing
suffering of large numbers of animals
Y N
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing
suffering of large numbers of animals
Y N
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the
direct impact of the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the
direct impact of the disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity
or the protection of endangered species or breeds, including the possible
disappearance or long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity
or the protection of endangered species or breeds, including the possible
disappearance or long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No).
Table 14: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for bluetongue
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final outcome
BTV-1–
24
BTV-25–
30
BTV-
16
D The risk posed by the disease in question can be effectively and
proportionately mitigated by measures concerning movements of animals
and products in order to prevent or limit its occurrence and spread
NC na NC
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL Y N N
Colour code: green = consensus (Yes/No); yellow = no consensus (NC); red = not applicable (na), i.e. insufﬁcient evidence or
not relevant to judge.
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3.5.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 16, 17
and 18). The proportion of Y, N or `na0 answers are reported, followed by the list of different
supporting views for each answer.
Reasoning supporting the judgement
Supporting Yes for 1 (cat.A):
• These serotypes have been detected only in a very limited part of the Union.
supporting Yes for 1 (cat.B):
• BTV-25–30 is only known to be endemic in a limited part of the Union, e.g. in the South of
Sardinia. Insufﬁcient surveillance has been conducted to determine the exact distribution in the
Union.
Reasoning supporting the judgement
Supporting Yes:
• The introduction of the virus into naive populations by spread of infected vectors (e.g.
windborne) or movement of viremic hosts, if happening in a suitable season and environment,
will lead to explosive transmission. From previous EFSA outputs based on mathematical
models, the expected level of vector transmission of BTV is high in the EU, with R0 values
between 3 and 10. Several factors are contributing to these high R0 values, such as the long
Table 15: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for bluetongue
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of
Annex IV of AHL and/or the following:
Final outcome
BTV-1–
24
BTV-25–
30
BTV-
16
E Surveillance of the disease is necessary for reasons relating to animal
health, animal welfare, human health, the economy, society or the
environment (If a disease fulﬁls the criteria as in Article 5, thus being
eligible to be listed, consequently category E would apply.)
Y N N
Colour code: green = consensus (Yes/No).
Table 16: Outcome of the expert judgement related to criterion 1 of Article 9 for BTV-25–30
Question
Final
outcome
Response
Y (%) N (%)
na
(%)
1(cat.A) The disease is not present in the territory of the Union OR
present only in exceptional cases (irregular introductions) OR
present only in a very limited part of the territory of the Union
NC 20 80 0
1(cat.B) The disease is present in the whole OR part of the Union territory
with an endemic character AND (at the same time) several
Member States or zones of the Union are free of the disease
NC 80 20 0
NC: non-consensus; number of judges: 10.
Table 17: Outcome of the expert judgement related to criterion 2.1 of Article 9 for all strain groups
Question
Final
outcome
Response
Y (%) N (%) na (%)
2.1 (cat.A) The disease is highly transmissible NC 9 91 0
NC: non-consensus; number of judges: 12.
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infectious periods in the host reported in experimental infections (e.g. medians of 17.5, 16.5,
21.3 and 16.5 dpi for EHDV, KASV, BTV and EEV, respectively).
Supporting No:
• Due to high variability in the transmission linked to biotic (host, vectors) and abiotic factors
(climatic factors, seasonality), BT cannot be considered generally highly transmissible.
Reasoning supporting the judgement
Supporting Yes:
• The risks of health consequences posed, particularly to na€ıve populations, are substantial.
Movement controls can limit risk, but within the context of ongoing transmission from a vector-
borne infection. It would still depend on vaccination.
• The occurrence and spread can be limited to some extent in some circumstances, e.g.
conﬁned areas (e.g. on the Balearic Islands) or where relevant vectors are not very abundant
(e.g. in Norway).
Supporting No:
• Measures in addition to movement restrictions would be needed to control the spread, e.g.
vaccination. For example, in France the disease has spread during a few months with
movement restrictions in place.
3.5.2. Outcome of the assessment of criteria in Annex IV for bluetongue for the
purpose of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 11–15. According to the
assessment methodology (EFSA AHAW Panel, 2017b), a criterion is considered fulﬁlled when the
outcome is ‘Yes’. With respect to different type of impact where the assessment is divided into current
and potential impact, a criterion will be considered fulﬁlled if at least one of the two outcomes is ‘Y’
and, in case of no ‘Y’, the assessment is inconclusive if at least one outcome is ‘NC’.
A description of the outcome of the assessment of criteria in Annex IV for bluetongue for the
purpose of categorisation as in Article 9 of the AHL is presented in Tables 19, 20 and 21.
Table 18: Outcome of the expert judgement related to criterion D of Article 9 for BTV (1–24) and
BTV-16
Question
Final
outcome
Response
Y
(%)
N
(%)
na
(%)
D The risk posed by the disease in question can be effectively and
proportionately mitigated by measures concerning movements of animals
and products in order to prevent or limit its occurrence and spread
NC 50 50 0
NC = non-consensus; number of judges: 10.
AHL assessment on bluetongue
www.efsa.europa.eu/efsajournal 55 EFSA Journal 2017;15(8):4957
Table 20: Outcome of the assessment of criteria in Annex IV for BTV-25–30 for the purpose of
categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
G
eo
g
rap
h
ical
d
istrib
u
tio
n
T
ran
sm
issib
ility
R
o
u
tes
o
f
tran
sm
issio
n
M
u
ltip
le
sp
ecies
M
o
rb
id
ity
an
d
m
o
rtality
Z
o
o
n
o
tic
p
o
ten
tial
Im
p
act
o
n
eco
n
o
m
y
Im
p
act
o
n
so
ciety
Im
p
act
o
n
an
im
al
w
elfare
Im
p
act
o
n
en
viro
n
m
en
t
Im
p
act
o
n
b
io
d
iversity
A NC NC na Y N N N N N N N
B NC Y na Y N N N N N N N
C N Y Y Y N N N N N N N
D N
E N
Table 19: Outcome of the assessment of criteria in Annex IV for BTV -1–24 for the purpose of
categorisation as in Article 9 of the AHL (CI = current impact; PI = potential impact)
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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A N NC Y Y Y N Y CI: N
PI: Y
Y N N
B Y Y Y Y Y N Y CI: N
PI: Y
Y N N
C Y Y Y Y N N N CI: N
PI: Y
Y N N
D NC
E Y
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According to the assessment here performed, BT complies with the following criteria of the Sections
1–5 of Annex IV of the AHL for the application of the disease prevention and control rules referred to
in points (a) to (e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BTV (1–24) complies with criteria 2.2, 2.3 and
2.4, but not with 1 and the assessment is inconclusive on criterion 2.1. BTV-25–30 complies
with criterion 2.3, but not with 2.4. The assessment is not applicable on criterion 2.2 and
inconclusive on compliance with criteria 1 and 2.1. BTV-16 complies with criteria 2.2 and
2.3, but not with 1 and 2.4 and the assessment is inconclusive on compliance with criterion
2.1. To be eligible for category A, a disease needs to comply additionally with one of the
criteria of the second set (3, 4, 5a–d) and BTV (1–24) complies with criteria 4, 5a and 5b,
but not with criteria 3, 5c and 5d. BTV-25–30 and BTV-16 do not comply with any of them.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BTV (1–24) complies with all of them. BTV-
25–30 complies with criteria 2.1 and 2.3, but not with criterion 2.4. The assessment is not
applicable on criterion 2.2 and inconclusive on compliance with criterion 1. BTV-16 complies
with criteria 1, 2.2 and 2.3, but not with criteria 2.1 and 2.4. To be eligible for category B, a
disease needs to comply additionally with one of the criteria of the second set (3, 4, 5a–d)
and BTV (1–24) complies with criteria 4, 5a and 5b, but not with criteria 3, 5c and 5d.
Therefore, the BTV strain group BTV-1–24 meets the criteria of Section 2 of Annex IV of the
AHL. BTV-25–30 and BTV-16 do not comply with any of them.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment BTV (1–24) complies with criteria 1, 2.1, 2.2
and 2.3, but not with 2.4. BTV-25–30 complies with criteria 2.1, 2.2 and 2.3, but not with 1
and 2.4. BTV-16 complies with criteria 1, 2.2 and 2.3, but not with 2.1 and 2.4. To be
eligible for category C, a disease needs to comply additionally with one of the criteria of the
second set (3, 4, 5a–d) and BTV (1–24) complies with criteria 5a and 5b, but not with
criteria 3, 4, 5c and 5d. BTV-25–30 and BTV-16 do not comply with any of them.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or
5 of Annex IV of the AHL and with the speciﬁc criterion D of Section 4, for which the
outcome for BTV (1–24) is inconclusive. BTV-25–30 and BTV-16 do not fulﬁl criteria of
Sections 1, 2, 3 or 5 of Annex IV of the AHL.
Table 21: Outcome of the assessment of criteria in Annex IV for BTV-16 for the purpose of
categorisation as in Article 9 of the AHL
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Article 9 criteria
1° set of criteria 2° set of criteria
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5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3
of Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons
relating to animal health, animal welfare, human health, the economy, society or the
environment. The latter is applicable if a disease fulﬁls the criteria as in Article 5, with which
BTV (1–24) complies, but not BTV-25–30 or BTV-16.
3.6. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
bluetongue. The Article 8(3) criteria are about animal species to be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that
such role is likely.’
For this reason the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.9 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017b), the main animal species to be listed for bluetongue serotypes/strain
groups according to the criteria of Article 8(3) of the AHL are as displayed in Table 22.
4. Conclusions and recommendations
4.1. Conclusions
ToR 4.2 Assess, by using appropriate criteria, the feasibility of grouping the currently known BTV
serotypes in appropriately deﬁned groups of serotypes sharing similar properties thus creating a
number of ‘BTV serotype groups’ separated by signiﬁcant different levels of impact on animal health
(e.g. most serious clinical symptoms in many individuals in large areas, mild symptoms to few
individuals within small areas or no symptoms at all in one or more BT susceptible species etc.).
• Repeated incursions of BT into Europe have been caused by different BTV strains, including
multiple serotypes, almost every year since 1998.
Table 22: Main animal species to be listed for BT serotypes/strains according to criteria of Article 8
(for details see Section 3.3.1.1)
Order Family Genus/species
Susceptible* BTV-1–24
(including BTV-16)
Artiodactyla Bovidae Several species, potentially all
Cervidae Several species, potentially all
Camelidae Several species, potentially all
BTV-25–30 Artiodactyla Bovidae Ovis aries, Capra hircus
Reservoir BTV-1–24
(including BTV-16)
Artiodactyla Bovidae Bos taurus, Ovis aries
Cervidae Cervus elaphus
BTV-25, -27, 30 Artiodactyla Bovidae Ovis aries, Capra hircus
Vectors BTV-1–24
(including BTV-16)
Diptera Ceratopogonidae Culicoides spp.
BTV-25, -27, -30 None
*: Zoo animals are not included in this table, since they are not present in large number in the EU. Some carnivores have been
demonstrated to be susceptible, although they may not be epidemiologically important.
9 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
AHL assessment on bluetongue
www.efsa.europa.eu/efsajournal 58 EFSA Journal 2017;15(8):4957
• The serotype classiﬁcation is useful for the production of serotype-speciﬁc vaccines, able to
protect against the homologous BTV, but the classiﬁcation based on serotypes is not sufﬁcient
to fully represent the genomic diversity and pathogenic heterogeneity of BTV: different virus
strains belonging to the same serotypes have had very different impacts on animal health in
outbreaks in Europe and elsewhere. Similar patterns could also be expected in the future, with
novel BTV strains occurring in Europe.
• For this reason, the assessment has been based on BTV strains rather than serotypes, thus
merging the classiﬁcation according to serotype and genetic diversity (genotype) with other
aspects of epidemiological relevance and animal health impact, including the time period and
geographical area of occurrence.
• A number of criteria were considered when analysing the animal health impacts of different
BTV strains including the intraherd morbidity, mortality and case-fatality rates for each BTV
strain, the mean number of outbreaks per week, and the ability to actively circulate within
different episystems, as calculated from ADNS data;
• The prediction of the impact of BTV strains is strongly hampered by knowledge gaps, and
therefore the ﬁeld observations are of paramount importance, both in the EU and in
neighbouring countries.
ToR 4.3 Review and classify the existing serotypes according to the outcome of the assessment in
point 4.2 above and assess whether any of the above serotypes/groups of serotype could be
candidates for a partial or total exclusion from the overall BT policy currently in place in the EU, in
particular due to their low level of virulence or pathogenicity.
• According to the assessment, the only BTV serotypes that could be partially excluded from the
overall BT policy currently in place in the EU, due to their low level of virulence or
pathogenicity, are the small ruminant-adapted strains, i.e. BTV strains belonging to serotypes
BTV-25, -26, -27 and related isolates.
ToR 5.1 Considering the outcome of the assessments and reviews referred to in paragraph 4
above, for each of the aforementioned groups of serotypes, or BT in general as appropriate, assess,
following the criteria laid down in Article 7 of the AHL, its eligibility of being listed for Union
intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, BTV (1–24) complies with all criteria of the ﬁrst
set and with three criteria of the second set and therefore can be considered eligible to be
listed for Union intervention as laid down in Article 5(3) of the AHL. BTV-25–30 and BTV-16 do
not comply with criterion 5 A(iii) of the ﬁrst set and therefore cannot be considered eligible to
be listed for Union intervention as laid down in Article 5(3) of the AHL.
ToR 5.2a For each of the aforementioned groups of serotypes, or for BT in general, if found
eligible to be listed for Union intervention, provide an assessment of its compliance with each of the
criteria in Annex IV to the AHL for the purpose of categorisation of diseases in accordance with Article
9 of the AHL;
• According to the assessment here performed, BTV (1–24) meets the criteria as in Sections 2
and 5 of Annex IV of the AHL, for the application of the disease prevention and control rules
referred to in points (b) and (e) of Article 9(1) of the AHL. Since BTV-25–30 and BTV-16
cannot be considered eligible to be listed for Union intervention as laid down in Article 5(3) of
the AHL, the assessment of its compliance with each of the criteria in Annex IV to the AHL for
the purpose of categorisation of diseases in accordance with Article 9 of the AHL is not
applicable.
ToR 5.2b For each of the aforementioned groups of serotypes, or for BT in general, if found
eligible to be listed for Union intervention, provide a list of animal species that should be considered
candidates for listing in accordance with Article 8 of the AHL.
• According to the assessment performed here, the animal species that can be considered for
listing for BTV-1–24 according to Article 8(3) of the AHL are as reported in Table 22 in
Section 3.6 of the present document: several (potentially all) species of Arctiodactyla belonging
to the families of Bovidae, Cervidae and Camelidae as susceptible species; domestic cattle,
sheep and red deer as reservoir hosts; midges insect of genus Culicoides spp. as vector
species for BTV-1–24.
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• Since BTV-25–30 and BTV-16 cannot be considered eligible for listing for Union intervention as
laid down in Article 5(3) of the AHL, the assessment of the animal species that are considered
to be listed in accordance with Article 8 of the AHL is not applicable.
4.2. Recommendations
Regarding ToR 4.3 about the BTV serotypes and strains that could be candidates for exclusion from
the overall BT policy currently in place in the EU, and ToR 5 about criteria of Article 5 and 9 of AHL for
assessing whether and which speciﬁc rules for the prevention and control would apply to BT, some
recommendations are here presented about the importance of surveillance and control of BTV and
related knowledge gaps:
• Surveillance data and knowledge of BTV strains and serotypes circulating in ‘source regions’
outside Europe is needed to provide a better understanding/prediction of the likelihood of an
incursion into/outbreak in Europe, via known geographic pathways, and the risk to European
animal populations should such an incursion occur.
• Surveillance is also needed to detect new BT outbreaks within Europe, to identify both their
signiﬁcance (severity, rate of spread, serotype, genotype and host species involvement) and to
inform the development of appropriate control strategies. For this reason, surveillance is
needed both within the EU and in neighbouring areas that can be a source of future
incursions.
• Appropriate surveillance strategies/methods, including sentinels and the importance of passive
surveillance, should be reﬁned and publicised.
• It would be helpful to have a well-established and identiﬁed surveillance network to detect
outbreaks at an early stage, in order to characterise the virus in cause and to assess their
relative economic importance and their impact on animal health.
• If new outbreaks can be identiﬁed early on, then an appropriate ‘ring vaccination’ strategy
could be developed to reduce/prevent viral spread and the potential for further outbreaks.
• If a broader cross-reactive (cross-serotype) BTV vaccine (ideally with DIVA capability and long
shelf-life) could be developed, this would potentially reduce the number of different vaccine
preparations required and therefore potentially reduce the costs of a vaccine bank.
Research needs
• There are important knowledge gaps with potential implications on future threats caused by
BTV incursions/persistence in Europe. Therefore, more knowledge would be helpful
concerning:
– Genetic markers in the virus for severe clinical signs/pathogenesis.
– Genetic markers in the virus for efﬁcient vector transmission by different vector
populations within the different episystems indentiﬁed in Europe. To do this, better
resources, including new vector-colonies and cell-lines for European vector species would
be particularly helpful.
– The risks posed by potential reassortment of genetic information among existing and novel
serotypes in the ﬁeld. It is not known whether this could lead to novel virus strains with
new biological characteristics, or new combinations of existing characteristics.
– The role of other vector species in the transmission of the novel serotypes.
– The persistence of virus including novel types in semen and abilities for vertical
transmission need more information.
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Abbreviations
ADNS Animal Disease Notiﬁcation System
AGID agar gel immunodiffusion
AHAW EFSA Panel on Animal Health and Welfare
AHL Animal Health Law
BT bluetongue
BTV bluetongue virus
BWC beef weaned calves
CDC Centers for Disease Control and Prevention
CFSPH Center for Food Security and Public Health
CFT complement ﬁxation test
CI conﬁdence interval
CITES Convention on International Trade in Endangered Species of Wild Fauna and Flora
CVMP Committee for Medicinal Products for Veterinary Use
DEET diethyl toluamide
DIVA distinguish infected from vaccinated animals
EEV equine encephalosis virus
EHDV epizootic hemorrhagic disease virus
ELISA enzyme-linked immunosorbent assay
FDA Food and Drug Administration
FMD foot and mouth disease
GMP Good Manufacturing Practice
ICBA Individual and Collective Behavioural Aggregation
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IgG immunoglobulin G
IUCN International Union for Conservation of Nature
KASV Palyam virus
LAV live attenuated vaccine
MRP Movement restriction policy
MS Member State
NSAID non-steroidal anti-inﬂammatory drugs
OIE World Organization for Animal Health
PCR polymerase chain reaction
RNA ribonucleic acid
RT-PCR reverse transcription polymerase chain reaction
RTS return to service
SN seroneutralisation/serum neutralisation
ToR Terms of Reference
TPT transplacental transmission
VP viral protein
AHL assessment on bluetongue
www.efsa.europa.eu/efsajournal 74 EFSA Journal 2017;15(8):4957
